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IABSTRACT
This project is an attempt to have a better understanding of
the role of carbohydrates in recognition and uptake of
allergens by the innate immune system. Glycosylation
analysis of different allergens like Der p 1, Fel d 1, Ara h 1,
Ber e 1, Der p 2, Bla g 2, Can f 1, Bromelain and Papain was
made using labelled lectins that can detect specific
carbohydrate moieties on proteins to reveal their pattern of
glycosylation. These experiments showed that all major
allergens are glycosylated and this represented a major first
step towards demonstrating a link between glycosylation and
allergen recognition by the innate immune system. N- and O-
glycosylation patterns were predicted in different allergens
and a difference in mannosylation and fucosylation was
detected between allergens and non-allergenic proteins. We
found that the main dominant sugars on allergens are 1,2 1,3
and 1,6 mannose, as detected by GNA lectin. We have also
showed that Der p 1 and Der p 2 possess 1,3 fucose in their
natural forms, thus concluding that Der p1 and Der p 2 have
part of the CCDs which are epitope structures for IgE. O-
glycosylation in allergens was also studied giving a better
understanding of the whole glycan structure in allergens.
The role of mannosylation in allergen recognition by the
immune system was investigated further. Different methods,
including recombinant expression, enzymatic and chemical
deglycosylation, were optimised to produce glycoforms of Der
p 1. A recombinant preparation of Der p 1 produced in Pichia
pastoris was used as a hypermannosylated form of the
allergen. These glycoforms served as useful tools in
addressing the nature of glycoallergen recognition by looking
II
at the uptake of hyper- and hypo-glycosylated preparations by
DCs, with confocal microscopy, ELISA and FACS as readouts.
Results indicate that deglycosylated forms of Der p 1 exhibited
minimal uptake by DCs compared to the natural and
hyperglycosylated recombinant allergen. Comparative analysis
of the hypermannosylated preparation of Der p 1 and its
natural counterpart, possessing less mannan, showed that the
recombinant form was taken up more readily by DCs at 37°C
and at 4°C. We also showed that these glycoforms bind to the
MR subfragment CTLD 4-7-FC, the C-type lectin carbohydrate
recognition domain. This binding significantly decreased when
the Der p 1 allergen was deglycosylated.
These results were confirmed further using confocal
microscopy imaging which also showed that recombinant Der
p 1 uptake is immediate, starting at 5 mins of incubation and
that a higher quantity accumulates inside the DC compared to
natural allergen. Recombinant and natural Der p 1 both co-
localised with MR, DC-SIGN and LAMP-2 lysosomal marker,
suggesting a key role for these receptors in allergen uptake
and a common fate for these preparations inside the DC.
Further experiments were done to show the effect of Der p 1
and Der p 1 glycoforms on TSLP secretion by epithelial cells,
which is known to induce Th2 driven immune responses. The
results show that TSLP secretion decreases significantly when
epithelial cells are challenged with deglycosylated
preparations of the same allergen. This may indicate a change
in the outcome of adaptive immune responses when a
deglycosylated allergen challenges epithelial cells.
In conclusion, this work has demonstrated a link between
allergenicity and glycosylation patterns in allergens. It
III
therefore appears that mannosylation is the dominant sugar
moiety associated with allergen uptake and recognition by
humans DCs, and this is in line with MR being the main
receptor involved in allergen binding by these cells.
IV
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Chapter 1 Introduction
1
CHAPTER ONE: Introduction
1.1 The immune system:
The environment that we live in is heavily populated with
pathogens and allergic substances that constantly challenge
our immune system, which has a primary aim of protecting
the host against infectious microbes. The immune response
therefore uses a complex array of molecules to control and
eliminate these pathogens. The human defence system
consists of a first line of physiological barriers like the skin
and lysozymes of tears and saliva. The second line of
defence is the innate immune system which boosts the
protection provided by the first line by recognising
conserved microbial components that are shared by large
groups of pathogens, and this is facilitated through different
kinds of cells like macrophages, dendritic cells, mast cells,
neutrophils, eosinophils, natural killer (NK) cells, and NK T
cells (Fig 1-1). The third line of defence is adaptive
immunity involving T and B lymphocytes. Any failure of
these mechanisms can lead to infection (Chaplin, 2006,
Roitt and Delves, 2001, Turvey and Broide, 2010).
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As the immune system uses potent effecter mechanisms to
clear pathogens, it is crucial to avoid destroying its own
tissues. This is referred to as self tolerance which leads to
the avoidance of reactions against self antigens and is
expressed in many parts of the innate and adaptive immune
responses. Failure of self tolerance would lead to
autoimmune diseases (Kay, 2000, Chaplin, 2010).
Upon encountering a pathogen the first line of defence is
the epithelial cells which express tight cell junctions and
cadherin-mediated cell interactions. The secreted mucus
layer and the epithelial cilia all help to clear the pathogen
(David, 2010, Hammad and Lambrecht, 2008, Chaplin,
2010). The innate immune defence works with the physical
barrier to fight the foreign antigen through complement
proteins, cytokines that regulate the function of other cells
and chemokines that attract inflammatory leukocytes. The
innate immune system includes membrane-bound receptors
that recognise pathogen associated molecular patterns
(PAMPs) and cytoplasmic proteins that bind these molecular
patterns expressed on the surfaces of invading microbes
(Turvey and Broide, 2010). For example, mannose binding
lectin binds mannose containing carbohydrates on
microbes, thus triggering the activation of the complement
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cascade to clear pathogen. Another example is Toll Like
Receptors (TLRs) which recognise diverse microbial epitopes
on pathogens and enable the innate immune system to
distinguish different groups of pathogens and to induce an
appropriate cascade of adaptive responses (Turvey and
Broide, 2010, Hammad and Lambrecht, 2008).
Fig 1-1: The human defence system consists of three lines
of defence; each uses a complex array of elements in trying
to clear infection. (Turvey and Broide, 2010)
The cellular elements of the innate immune system includes
neutrophils, monocytes and macrophages which are
phagocytic and can clear the pathogen through binding to
immunoglobulin, complement or both. They also produce
cytokines like IL-12 and IFN-ǄWKDWDLG LQWKHUHJXODWLRQRI
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adaptive immune responses. Some of the newly indentified
cytokines in innate immunity include IL-25, IL-33 and TSLP
(Thymic Stromal Lymphopoietin) which induce the secretion
of Th2 inflammatory cytokines (Fig 1-2) (Kim et al., 2010).
NK cells are a distinct lineage of lymphoid cells that kill
virally infected cells. Also, dendritic cells (DCs) play a vital
role in between the innate and adaptive immune system as
antigen presenting cells (APCs). They express MHC I and
MHC II, which facilitate recognition of processed antigen by
T cells (Fig 1-2) (Kim et al., 2010, Chaplin, 2010).
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Fig 1-2: The cellular elements of the innate immune
defence system. (Kim et al., 2010)
The adaptive immune system includes T and B lymphocytes
with their antigen specific receptors. T cells use these
receptors to identify cells infected by pathogens and destroy
them. T cells recognise molecular complexes of the
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pathogenic antigen and a self-structure. The self-structures
are either MHC I molecules that bind fragments of proteins
that have been synthesised within the cell or MHC II
molecules that bind to fragments of proteins that have been
ingested by the cell and proteolytically processed.
Subsequently, T cells differentiate to CD8 cytotoxic T cells
that kill the infected cell or DC4 T helper cells that regulate
the cellular and humoral immune responses (Roitt and
Delves, 2001, Chaplin, 2010). CD4 T cells can differentiate
into Th1, Th2 or Th17 depending on the nature of the
cytokines present. IL-12 and IFN-Ǆ SURGXFHG E\
macrophages or NK cells induce differentiation towards Th1;
IL-4, IL-5, IL-9 and IL-13 induce differentiation towards a
Th2 immune response; a connection between high levels of
thymic stromal lymphopoietin (TSLP) secretion and the
induction of Th2 immune responses has been established.
TSLP is an IL-7-like cytokine which is released by primary
human epithelial cells in response to certain microbial
products. TSLP can activate DCs and increases their
expression of the ligand for the T cell costimulatory
molecule OX40 thus enhancing Th2 immune responses.
Other cytokines have been shown to enhance Th17
Chapter 1 Introduction
7
inflammatory responses like TGF-ǃ and IL-6 (Asarch et al.,
2008, Chaplin, 2010, Bettelli et al., 2007, Kim et al., 2010).
B cells on the other hand function to produce antigen
specific immunoglobulins (Igs) that attack the foreign
antigens and facilitate their presentation to T cells. B cell
maturation and Ig production are dependent on Th cell
cytokine production. T cell-derived IL-10 causes switching
to IgG1 and IgG3. IL-4 and IL-13 cytokines cause switching
to IgE, while TGF-ǃ causes switching to IgA. IFN-Ǆ or some
other undefined product of Th1 cells appears to induce
switching to IgG2 (Chaplin, 2010).
1.1.1 Atopy and Allergy:
The term allergy was introduced in 1906 by Von Pirquet in
trying to describe uncommitted biological responses in the
body leading either to immunity or hypersensitivity
reactions. Since then, allergic diseases have been the focus
of interest for scientists in trying to unveil the dogma
behind what makes an allergen. The answer to this
question is important in understanding the mechanism
behind hypersensitivity responses and to design a better
therapeutic approach to allergic diseases like asthma, atopic
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eczema and allergic rhinitis which are common causes for
chronic ill-health (Robinson et al., 1997, Kay, 2000). It is
thought that allergens might possess common surface
features or glycosylation patterns that enable the innate
immune defence to recognise them as Th2 inducers. The
identification of common structural features among
allergens is important in understanding the role of allergens
in inducing hypersensitivity reactions (Shreffler et al.,
2006). Research on the glycosylation features of allergens
have suggested that carbohydrates displayed by allergens
could be unique in structure or orientation and thus being
recognised by the mannose receptor on dendritic cells,
thereby favouring Th2 polarisation and allergy (Shakib et
al., 1998, Shreffler et al., 2006, Altmann, 2007, Taylor et
al., 2005). In general, non-atopic individuals will exhibit
low level of immunological response to allergens, while
atopic individuals will mount an exaggerated immune
response to these generally innocuous substances, which
has all the hallmarks of type I hypersensitivity, such as
production of high levels of IgE antibody and Th2 type
cytokines (Kay, 2000).
The immune system is the sole barrier of defence against
infection; it prevents the pathogen from breaching the body
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by providing immediate innate immunity and a later specific
adaptive immunity. Innate immunity involves inflammation,
complement system and special leukocytes like mast cells,
eosinophils, basophils, natural killers and phagocytes. The
adaptive immune cells involve B and T lymphocytes. B cells
express different antibodies directly attacking the foreign
antigen, while T cells, which are divided into two subtypes,
cytotoxic T cells and helper T cells, recognise the foreign
antigen by processing and presenting the antigen by a self
receptor called the major histocompatibility complex (MHC).
Cytotoxic T cells recognise antigen coupled with MHC I,
while helper T cells recognise antigen coupled with MHC II.
The Th cells themselves differentiate into three subtypes
called Th1, Th2 and Th17 according to their cytokine
production upon stimulation (Tada T, 1978, Bettelli et al.,
2007, Asarch et al., 2008, Bird, 2008). It is thought that
IFN-Ǆ and IL-12 stimulate Th1 immune responses which
fight intracellular pathogens, while production of IL-4, IL-5,
IL-13 and TSLP stimulate Th2 immune response which
attack extracellular pathogens by regulating antibody
production (Fig 1-3) (Roitt and Delves, 2001, SL., 2007,
Reiner., 2007, Minton, 2008, Hammad and Lambrecht,
2008).
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Allergens can trigger the production of TSLP by airway
epithelial cells, which induces DCs to recruit Th2 cells into
the airway (Fig 1-3) (Ziegler and Artis, 2010, Hammad and
Lambrecht, 2008, Li et al., 2010). Th 17 cells are thought to
be regulated by IL-23, these cells secrete IL-17 and IL-22
which are inflammatory cytokines suggesting a role for
these cells in mediating inflammation and in protection
against extracellular pathogens. Investigators later found
that transforming growth factor (TGF)-ǃ1, IL-6, and IL-15
stimulated initial Th17 differentiation from naive T cells
(Asarch et al., 2008, Bettelli et al., 2007).
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Fig 1-3: The role of TSLP in driving DC maturation towards
supporting Th2 immune responses. A. Allergen triggering
the activation of Tslp gene transcription. B. TSLP induces
immediate innate immune functions in dendritic cells (DCs)
leading to chemokine-driven recruitment of Th2 cells. C. In
mast cells, there is immediate release of the Th2-type
effector cytokines that can attract and activate eosinophils
in a T̻cell independent manner. D. Following innate
immune induction, TSLP triggers the maturation of DCs so
that they migrate to the mediastinal lymph nodes and
induce the polarisation of inflammatory Th2 cells in an
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OX40L-dependent fashion. E. The effector cytokines
produced by adaptive Th2 cells and mast cells trigger the
salient features of asthma. F. Effector cytokines can also
perpetuate TSLP-driven inflammation by further triggering
the release of TSLP by airway epithelial cells. This process is
enhanced by epithelial-cell production of the pro-allergenic
cytokine IL-25. CCL11, CC̻chemokine. (Hammad and
Lambrecht, 2008)
All this protection depends on the ability of the immune
system to distinguish between self and non-self antigens.
Allergens can destabilise the immune system; they have the
ability to induce IgE responses, which involve the
sensitisation of B, T and dendritic cells. They can also
induce clinical responses on subsequent exposure which
involves immediate and late hypersensitivity reactions.
When the immune system produces large amounts of IgE,
the individual is said to be atopic. The most significant
characteristic of atopy is having high IgE levels in patients
serum against a specific allergen (Navarro et al., 2007,
Platts-Mills et al., 2007).
Atopy and allergy are often used interchangeably but they
are different. Allergy is an excessive immune response to a
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foreign antigen regardless of the mechanism, while atopy is
a profuse IgE mediated immune response (Johansson et al.,
2004, Dreborg, 2003). Atopy in general includes eczema,
allergic conjunctivis, allergic rhinitis and asthma (Andrew,
2004). Upon inhaling aero-allergens, non-atopic individuals
have low grade of immunological responses, they produce
IgG1 and IgG4 antibodies and they also mount a Th1
immune response by the production of IFN-Ǆ and IL-12,
while atopic patients mount an exaggerated IgE immune
response and tend to polarise a Th2 immune phenotype
(Figure 1-1) by producing IL-4, IL-5 and IL-13 (Ebner et al.,
1995, Wierenga et al., 1990, Bird, 2008). Factors
influencing whether Th1 or Th2 will dominate immune
responses are the dose of allergen, length of exposure and
the avidity between T cells and antigen presenting cells
(Rogers and Croft, 1999). It is suggested that atopy and
allergic asthma are less frequent in people exposed to
agents in soil, air and water as bacteria and viruses, the so
called hygiene hypothesis. This will produce an IL-12 rich
environment, thus enhancing Th1, rather than Th2, immune
responses (Kapsenberg et al., 2000, Kay, 2000, Platts-Mills
et al., 2007, Rogers and Croft, 1999, Minton, 2008)
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The term hypersensitivity is used to describe the
exaggerated adaptive immune response against a specific
antigen causing tissue damage. Hypersensitivity reactions
were classified into four classes according to Coombs and
Gell. Types I, II and III are antibody mediated while type IV
is T cell mediated (Johansson et al., 2004). Type I
hypersensitivity underlies all atopic and most allergic
disorders as it is caused by a high IgE influx, while in type
II IgM and IgG antibodies cause direct cell destruction
involving mostly endogenous antigens. Type III
hypersensitivity is caused by IgG antibodies that are mainly
directed against soluble antigens forming immune
complexes, and type IV includes Th1 immune responses
and is considered to be T cell mediated (Dreborg, 2003,
Johansson et al., 2004, Roitt and Delves, 2001, Brooks et
al., 2004).
1.1.2 Type I hypersensitivity:
Type I hypersensitivity, which is also called anaphylactic or
immediate hypersensitivity, is characterised by an
immediate damaging response to a secondary exposure of
an allergen resulting in recruitment of mast cells and
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basophils and production of IgE antibody causing extreme
inflammatory responses. When mast cells are triggered they
release histamine, prostaglandins and leukotrienes. Good
examples for this type of hypersensitivity are allergic
conjunctivitis, allergic rhinitis and asthma (Saito, 2007,
Roitt and Delves, 2001, Gould and Sutton, 2008).
The mechanism of the reaction involves IgE production in
response to certain allergens. Upon inhalation of an
allergen, Th2 driven responses occur. B cells switch to IgE
isotype production upon exposure to the Th2 cytokines IL-4
and IL-13. Basophils and mast cells become sensitised with
IgE and upon subsequent exposure to allergens undergo
degranulation and release inflammatory mediators like
histamine that cause vasodilatation and smooth muscle
contraction. This results in an immediate inflammatory
response that starts within seconds causing rhinorrhea,
itching and anaphylaxis; it is then followed by a late phase
response that takes six to eight hours to develop. At a later
stage eosinophils, platelets and neutrophils are also
triggered. Platelet activation factor (PAF) amplifies the
reaction by causing platelet aggregation and more release
of histamine. Eosinophil and neutrophil chemotactic factors
Chapter 1 Introduction
16
attract eosinophils and neutrophils, respectively (Akdis,
2006, Roitt and Delves, 2001, Brooks et al., 2004).
1.1.3 Role of different cell types involved in
the allergic cascade:
In some cases allergy is a systemic reaction involving
multiple organ systems. It begins when the body
encounters an allergen which results in type I
hypersensitivity reactions where B cells produce IgE
antibodies and T cells regulate IgE production by producing
different cytokines like IL-4, IL-5, IL-9 and IL-13. Mast cells
and basophils undergo degranulation and release histamine
causing vasodilation of capillaries (Kay, 2000, Saito, 2007,
Gould and Sutton, 2008).
Other cells involved in allergy are dendritic cells (DCs)
which are specialised antigen presenting cells (APCs) that
are able to recognise the antigen at the site of entry and
present it to naive T helper cells in draining lymph nodes,
which will lead to the development of Th1 or Th2 immune
responses. It has been shown that monocyte derived
dendritic cells induce a Th1 response; whereas CD4+ CD3-
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CD11c- derived dendritic cells induce a Th2 immune
response (VINEY, 1999). Others argue that it is the amount
of IL-12 secreted by dendritic cells that determine the
immune response pathway that follows (Kalinski et al.,
1999).
Research on the effect of Der p 1 (a major house dust mite
allergen) on dendritic cells showed that enzymatically active
Der p 1 cleaves CD40 from the DC surface leading to
suppression of IL-12 secretion and this initiates the
establishment of a Th2 cytokine profile upon co-culturing
these DCs with naïve T cells (Ghaemmaghami et al., 2002).
DC use numerous C-type lectins, such as MR, DC-SIGN,
dectin-1, langerin, and DEC-205, for antigen uptake.
(Erbacher et al., 2009). These lectin receptors are
expressed by DCs and are involved in the recognition and
capture of many glycosylated self-antigens and pathogens.
The mannose receptor (MR), which is a C-type lectin
receptor, recognises a wide range of both endogenous and
exogenous ligands and has been implicated in pathogen
recognition (Gazi and Martinez-Pomares, 2009). It is
composed of 3 regions; an extracellular region containing a
cysteine rich domain (CR domain), a domain containing
fibronectin type two repeats (FNII) and multiple C-type
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lectin-like carbohydrate recognition domains (CTLDs), a
transmembrane domain and a short cytoplsmic tail (Fig 1-4)
(Taylor et al., 2005). MR recognises mannose, fucose and
N-acetylglucosamine on the surfaces of microorganisms and
carbohydrate recognition is mediated by CTLD 4-7 (Kerrigan
and Brown, 2009, Taylor et al., 2005).
Fig 1-4: Structure of the Mannose Receptor (Taylor et al.,
2005).
There is an abundant expression of MR on monocyte
derived DCs, which leads to the assumption that MR is used
as an antigen recognition tool by these cells. When DCs are
treated with PAM-1 monoclonal antibody that is specific to
MR, DCs could not produce Th1 recruiting chemokines but
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released Th2 and T regulatory cell recruiting chemokines,
which are negative regulators of Th1 responses (Fig 1-5).
When MR and TLR2 were co-expressed on the same cell, IL-
8 secretion was detected, thus MR has been found to be
involved in the triggering of a regulatory-promoting
phenotype in human DCs (Gazi and Martinez-Pomares,
2009). It has been suggested that MR on DCs could play a
role in the recognition and uptake of Der p 1 allergen and
this has been shown through labeling Der p 1 and observing
its uptake by DCs. The uptake of Der p 1 can be inhibited
by mannan, the natural ligand for MR, thus demonstrating
the importance of MR in the recognition of Der p 1 (Deslee,
Gt et al. 2002). The silencing of MR expression on
monocyte-derived DCs reverses the Th2 cell polarisation
bias, driven by Der p 1 allergen exposure, through
upregulation of IDO activity (Deslee et al., 2002, Royer et
al., 2010).
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Fig 1-5: MR co-operation with other signalling receptors to
control cytokine secretion. MR engagement by Man-LAM has
a negative effect on the production of IL-12 in response to
LPS in human DC (a). Co-expression of MR and TLR2 is
required for IL-8 production in response to P. carinii (b).
Additionally, engagement of MR by a specific mAb or
selected ligands leads to the production of anti-
inflammatory mediators (c). MR-mediated internalisation
favours cross-presentation (d) in addition to MHCII-
mediated presentation of exogenous antigens (Gazi and
Martinez-Pomares, 2009).
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Another C-type lectin receptor on DCs is DC-SIGN (dendritic
cell-specific ICAM-grabbing non-integrin), which was
recently discovered as a mannose specific C-type lectin
which was found to bind ICAM-3 (DC specific intercellular
adhesion molecule 3) with high affinity, thus initiating the
contact of DCs with resting T cells (Geijtenbeek et al.,
2000). It was reported that Der p 1 cleaves the
extracellular portion of DC-SIGN indicating that it is also a
target for Der p 1 allergen and is therefore implicated in
driving allergic responses (Furmonaviciene et al., 2007).
1.2 The House Dust Mite Allergens:
There are different kinds of allergens that induce atopic
allergic diseases; these include indoor allergens, pollen
allergens and food allergens. The most prevalent indoor
allergens are the house dust mite allergens of the species
Dermatophagoides pteronyssinus and Dermatophagoides
farinae which are categorised into group I and group II
allergens (Kay, 2000, Thomas W. R. et al., 2002). Der p 1
and Der f 1 are cysteine protease allergens and are said to
be within group I allergens, while group II allergens, which
include Der p 2 and Der f 2, are still being studied for their
functional and structural similarities (Chapman et al.,
2007). The cysteine protease activity in house dust mite
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allergens has been directly linked to cleaving cell surface
molecules that control IgE synthesis, thus promoting Th2
immune responses that lead to asthma (Furmonaviciene et
al., 2007, Thomas W. R. et al., 2002, Shakib et al., 1998,
Deb et al., 2007).
In recent years many allergens have been produced as
recombinant proteins expressed in bacteria and yeast,
leading to a growing family of recombinant allergens like
Bet v 1, Der p 1, Der p 2, Der f 1 and Ara h 1 (Chapman et
al., 2000, Best et al., 2000). These have been shown to be
a useful tool in studying T and B cell recognition of allergens
as well as IgE regulation. The three dimensional structure
for allergens, including Bet v 1, Der p 1, Der p 2 and Ara h
1, has been determined by NMR, X-ray crystallography and
computer based molecular modelling. Sequence homology
searches have revealed the biological function of different
allergens (Nishiyama et al., 1995, Chapman et al., 2000,
Chua et al., 1988).
1.2.1 The Der p 1 allergen:
Epidemiological studies showed a relationship between
exposure to house dust mite allergens and the increase in
asthma cases (Kay, 2000, Richardson et al., 2005, Sharma
et al., 2003). Allergens from the house dust mite
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Dermatophagoides pteronyssinus are commonly associated
with hypersensitivity reactions. This type of allergy affects
30% of the population in developed countries, which is due
to the increased exposure to indoor allergens. There are
fifteen different Der p allergens that have been identified to
date according to the allergen nomenclature committee
http://www.allergen.org/Allergen.aspx, and it has been
shown that homes of people suffering from house dust mite
allergy contain high levels of Der p 1 allergen, which is
considered one of the major allergens in western countries
(Guy et al., 1995, Adnan et al., 1996, Tsai et al., 2005,
O'Neil et al., 2006, Weghofer et al., 2005, Thomas W. R. et
al., 2002).
Der p 1 is a 25 kDa allergen with cysteine protease activity.
It was identified in 1969 by Voorhorst and is now
considered the most significant house dust allergen. It is
produced in the mid gut of the mite and found in mite
faecal pellets (Voorhorst R 1969). The role of Der p 1 is to
help in digestion of food substrates in mites, like human
keratin, and it is found in high concentrations in house dust
mite faeces, which when inhaled could provoke allergy
attacks and asthma.
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It has been shown that up to 90% of individuals who are
sensitised to house dust mite allergens are actually
responsive to Der p 1 (Sharma et al., 2003, Richardson et
al., 2005, Thomas and Smith, 1998). Wan et al, (2000)
found that Der p 1 was able to break the tight junctions of
the epithelial cells, suggesting a role for Der p 1 in lung
epithelium permeability which contributes to sensitisation
and allergic responses. Also, it has been clearly shown that
Der p 1 affects both innate and adaptive immune
responses. For instance, by using its cysteine protease
activity, it induces mast cell and basophil degranulation
which influence IgE antibody production. It has also been
shown that Der p 1 can cleave cell surface molecules that
control IgE synthesis, like CD25 on T cells, CD23 on B cells
and CD40 on dendritic cells (Ghaemmaghami et al., 2002,
Shakib et al., 1998). Der p 1 was also shown to cleave DC-
SIGN on dendritic cells and DC-SIGNR expressed by
endothelial cells (Furmonaviciene et al., 2007).
Investigators have shown that proteolytically active Der p 1
suppresses IFN-Ǆ and enhances IL-4 production by both
CD4 and CD8 cells, thus enhancing IgE production by B
cells and supporting an overall type 2 cytokine response
(Ghaemmaghami et al., 2001). It was shown that when Der
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p 1 cleaves CD40 from dendritic cells, that will lead to the
production of less IL-12 and will stimulate CD4 T cells to
produce more IL-4 and less IFN-Ǆ which again directs the
immune system towards a Th2 immune response (Figure 1-
6).
Der p 1, as well as Der f 1, has been shown to act on lung
epithelium by cleaving the lung surfactant proteins (SP) A
and D which are carbohydrate binding proteins. This results
in diminishing their ability to bind and neutralise
glycoallergens (Deb et al., 2007). Der p 1 also inhibits Į1-
antitrypsin, which is an anti-protease forming part of the
mucosal innate defence system. The neutralisation of Į1-
antitrypsin could therefore weaken host defences against
epithelial cell damage, and this may harm airway tissues
(Sharma et al., 2003).
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Fig 1-6: The protease activity of Der p 1 favours hyper-IgE
production and allergy. Der p 1 proteolytically digests
surface molecules on dendritic cells (DC), mast cells (MC), T
cells (TC), T regulatory (Treg) cells and B cells (BC) leading
to uncontrolled IgE production and allergy (Shakib et al.,
2008).
1.2.2 The molecular structure of Der p 1:
The molecular structure of Der p 1 has been the subject of
many studies. The gene encoding Der p 1 has been cloned
and sequenced, and the cDNA clone coding for Der p 1 was
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first sequenced by Chua et al., (1988). It encodes for a 222
residue mature protein having a molecular weight of 25,371
and containing four potential N-glycosylation sites. Der p 1
is produced in the mite as an enzymatically inactive
proenzyme that becomes active after cleavage of the
propeptide. When Der p 1 is extracted from the mite faeces
it is in the mature form (nDer p 1) (Chua et al., 1988, Meno
et al., 2005, de Halleux et al., 2006). Meno et al, (2005)
were able to produce a recombinant form of Der p 1 that is
hypoglycosylated using an N132E mutation that rendered
the protein non-susceptible to glycosylation at this site. The
recombinant form was expressed in Pichia pastoris. This
study provided a detailed description of the crystal structure
of the pro-form of Der p 1 and the antibody binding
properties of pro and mature Derp 1.
De Halleux et al also determined the 3-dimentional
crystallographic structure for both glycosylated and
unglycosylated forms of recombinant Der p 1 by producing
a recombinant pro-Der p 1 exhibiting allergenicity similar to
its natural counterpart. They confirmed this by
demonstrating that the recombinant form was recognised
by human IgE and activated basophils just as well as the
natural one. The crystal structure showed that the molecule
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preserves a C1 cysteine protease fold consisting of two
domains and a catalytic site between them. This study also
showed the existence of a magnesium binding site in Der p
1 and determined the epitope binding regions (Fig 1-7).
Better understanding of the molecular structure of Der p 1
will clearly offer the chance to design specific inhibitors of
allergens both in vitro and in vivo.
Fig 1-7: Ribbon diagram of mature Der p 1. A view of the
Der p 1 dimer (de Halleux et al., 2006).
1.2.3 Recombinant Der p 1:
Almost a decade ago several groups tried isolating and
analysing cDNA coding for allergens in order to identify
proteins inducing IgE responses in humans. It was then that
similarities between allergens and other proteins were
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discovered. Der p 1, for example, was considered a papain-
like protease. In recent years, a number of different
recombinant allergens have been produced which have
functional and immunological similarities to their native
counterparts. Recombinant allergens were shown to be
useful tools in studying allergen specific B and T cell
immune responses.
One way of recombinant allergen construction requires
mRNA to be prepared from the tissue in question then
reversibly transcribed into cDNA, which can then be used to
build a cDNA library that can be screened with antibodies or
DNA probes (Valenta and Kraft, 1995).
The first few attempts to produce recombinant Der p 1 in S.
cerevisiae and E. coli were unsuccessful as the allergen was
poorly expressed and had a weak IgE binding activity.
Therefore, investigators tried finding a different expression
system that could yield high concentration of protein
secretion and would be easy to manipulate.
1.2.4 Expression of recombinant Der p 1 in
Pichia pastoris:
It has become increasingly popular in recent years to use
yeast as a cellular host for the expression of recombinant
proteins. Pichia is easy to manipulate, faster and less
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expensive to use than other eukaryotic expression systems,
with the advantage of having higher expression levels and
the ability to perform post-translational modifications like
glycosylation (Cereghino and Cregg, 2000, Hamilton and
Gerngross, 2007, Jacquet et al., 2002, Yokoyama, 2003)
Pichia pastoris needs methanol as a carbon source, which it
oxidises to formaldehyde by an alcohol oxidase enzyme.
Two genes in Pichia codes for alcohol oxidase AOX1 and
AOX2. The AOX1 gene has been isolated and a plasmid
containing the AOX1 promotor is used to express the gene
of interest. For the transcription of the desired protein,
growth on glycerol with methanol induction is required
(Cereghino and Cregg, 2000, Cereghino et al., 2002).
Expression of protein in Pichia has the advantage of
generating large amount of the desired protein in high
concentrations with post-translational modifications like
disulfide bonding and protein glycosylation. The desired
protein is secreted in the culture media with low amounts of
the yeasts own expressed proteins, using vectors such as
pPICZalphaA that contains the AOX1 promoter that
regulates methanol-induced expression of the gene of
interest. This vector has also the alpha-factor secretion
signal for secretion of the recombinant protein, a Zeocin
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resistance gene for selection and a C-terminal peptide
containing the c-myc epitope and a polyhistidine (6xHis) tag
for detection and purification of the recombinant protein
(Cereghino et al., 2002, Cereghino and Cregg, 2000).
Recently, several groups successfully produced recombinant
forms of Der p 1 allergen expressed in P. pastoris with full
enzymatic and IgE binding activity (Meno et al., 2005, de
Halleux et al., 2006, Takai et al., 2005, van Oort et al.,
2002). The advantages of using P. pastoris in expressing
Der p 1 is that it leads to high level of secretion; this
system is also feasible for fermentation to high cell density
and can be scaled up without losing any yield (Jacquet et
al., 2002). It is possible to modify the expressed
recombinant Der p 1 to hyperglycosylated and
hypoglycosylated forms using point mutations and
enzymatic deglycosylation. The four possible glycosylation
sites on Der p 1 are N16, N82, N132 and N 195; by
mutating these sites the degree of glycosylation can be
controlled in recombinant Der p 1 (Meno et al., 2005). In
conclusion, this system is faster and less expensive than
other eukaryotic systems and it produces enzymatically and
immunogically active recombinant forms of Der p 1 (Jacquet
et al., 2002, Meno et al., 2005).
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1.2.5 Glycosylation in allergens:
Many allergens are glycosylated which raises the possibility
that glycosyl groups may contribute to their allergenicity.
Oligosaccharides are naturally added to proteins during
synthesis in the ER and Golgi of the cells (Huby et al.,
2000). Glycosylation is either N-linked where
oligosaccharides are covalently attached to Asparagine, or
they are O-linked to Serine/Threonine amino acids. This
depends on which glycosylation motif is present within their
primary amino acid sequence (Huby et al., 2000, Fötisch
and Vieths 2001).
The study of glycosylation in allergens began in the
seventies when Bromelain, the protease from pineapple,
was found to contain oligosaccharides with structural
features that had not been found in mammalian
glycoproteins, Į1, 3-fucose and xylose (Bardor et al., 2003,
Ishihara et al., 1979). These asparagine-linked
carbohydrate moieties were found to be the most abundant
in plants, insects and mammals but not in higher Apes such
as humans, and therefore formed the structural basis of
what is known as cross-reactive carbohydrate determinants
(CCDs) (Commins and Platts-Mills, 2009, Altmann, 2007).
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The link between CCDs and allergy was made after showing
that Į1,3-fucose and xylose are the most common
carbohydrate epitopes recognised by human IgE antibodies.
Studies have shown that up to 30% of allergic patients
develop a specific anti-glycan IgE and that glycosylated
epitopes make very good B cell epitopes (Mari, 2002,
Commins and Platts-Mills, 2009, Calabozo et al., 2002,
Okano et al., 1999, Petersen et al., 1998). Furthermore, it
has been recently shown that IgE antibodies against CCD
can produce clinically serious reactions specially in those
reacting to mammalian galactose Į1,3 galactose (Commins
and Platts-Mills, 2009, Sandrine et al., 2009, Commins and
Platts-Mills, 2010).
Glycosylated proteins can show higher uptake rates by DCs
than their non-glycosylated counterparts. Hilmenyuk et al
showed recently that glycation of ovalbumin increased its
internalisation significantly by immature DCs and that it
induced a Th2 immune response (Hilmenyuk et al., 2010,
Anne et al., 2010). The cause of this phenomenon can be
traced to the presence of lectin receptors like MR or DC-
SIGN on DCs. This notion therefore supports the hypothesis
that APCs recognise glycans on allergens efficiently and this
Chapter 1 Introduction
34
may eventually mediate an enhanced Th2 immune response
(Fig 1-8).
Fig 1-8: Surface sugar moieties on allergens bind allergen
specific pattern recognition receptors like MR leading to Th2
responses (Shakib et al., 2008).
1.3 Aims of the project:
Much work was carried out over the years to understand the
allergenicity of Der p 1 and its recognition by the immune
system. However, the role of protein glycosylation in allergy
has not been elucidated yet, but recent work in our lab has
shown that the uptake of Der p 1 by the mannose receptor
on dendritic cells is dependent on the level of Der p 1
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glycosylation (Royer et al., 2010). The aim of this study is
therefore to elucidate the role of glycosylation in Der p 1
recognition by the immune system, by producing different
glycoforms of recombinant Der p 1 that could then be
tested in dendritic cell uptake experiments.
Specific aims of the projects:
1. Investigate the pattern of glycosylation (quantity and
quality) of major allergens from different sources including
Der p 1.
2. Express Der p 1 in P. pastoris yeast cells to produce a
recombinant form of Der p 1.
3. Produce different glyco-forms of recombinant Der p 1
using point mutation of specific glycosylation sites.
4. Produce different glyco-forms of recombinant Der p 1
using enzymatic and chemical deglycosylation.
5. Examine the allergenicity of these different glyco-forms
of Der p 1 compared to their natural counterparts and
assess their recognition by different cell surface receptors.
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CHAPTER TWO: Investigating the pattern of
glycosylation in allergens.
2.1 Introduction:
Allergens are foreign proteins that induce type I
hypersensitivity reactions. In other words, they elicit Th2
immune responses, thus inducing IgE production and allergy.
It has been suggested that what might differentiate allergens
from other non-allergenic proteins lies in their protease
activity, surface features and/or glycosylation patterns. These
three features either singly or collectively might render some
proteins allergenic (Shakib et al., 2008, Furmonaviciene et al.,
2005, Huby et al., 2000). The protease activity and the peptide
surface features of allergens have been discussed thoroughly in
the literature (Russano et al., 2008, Shakib et al., 2008, Wills-
Karp et al., 2009). The glycosylation pattern of allergens,
however, is only now beginning to get attention as possible
distinguishing features of these proteins. Much of the research
in this area has so far only dealt with the determination of the
carbohydrate content of allergens, without much consideration
for the whole carbohydrate structure and the pattern of
glycosylation (Poltl et al., 2007, Fötisch and Vieths 2001,
Altmann, 2007).
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The role of carbohydrates in allergy has been discussed in
recent years and remains controversial (Altmann, 2007,
Fötisch and Vieths 2001, Paschinger et al., 2005, Okano et al.,
1999). It is well known that carbohydrate determinants are
the most frequently encountered epitope structures for IgE
(Fötisch and Vieths 2001, Chunsheng et al., 2008), and as
such have been named Cross-reactive Carbohydrate
Determinants (CCD). These determinants are asparagine linked
carbohydrate moieties and they mainly consist of xylose and
core-3-linked fucose which forms the vital part of two
independent IgE epitopes (Chunsheng et al., 2008). These
CCDs are mainly found in plants, insects and parasites, but are
absent in mammals and are therefore immunogenic
(Paschinger et al., 2005, Altmann, 2007)
In an attempt to have a better understanding of the role of
carbohydrates in allergy, the most commonly encountered
allergens were examined in this chapter for their carbohydrate
content by using labelled lectins that react to specific sugar
moieties (Table 2-1). Defining the quantity and quality of
glycosylation in allergens is a major first step towards
demonstrating a link between carbohydrates and allergen
recognition by the innate immune system. Most of the previous
research on allergen glycosylation concentrated on the
presence of xylose and fucose (Altmann, 2007, Chunsheng et
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al., 2008). In this work, the detection of 1,2 1,3 and 1,6
mannose was done using the lectin GNA that reacts with high
mannose structures on proteins. It was also possible to identify
1,3 fucose in allergens via a specific antibody. Examining O-
glycosylation in allergens was done using MAA, SNA, PNA and
DSA which collectively recognise 1,3 and 1,4 galactose in
addition to sialic acid. Collectively, these antibodies helped to
define the prevalence of different glycan moieties in allergens.
2.2 Materials and methods:
2.2.1 Allergen and protein sample preparation:
Purified natural and recombinant Der p 1, Der p 2, Fel d 1,
deglycosylated Fel d 1 (missing a major glycosylation site),
Can f 1, Ara h 1, Bla g 2 and Ber e 1 were bought from Indoor
Biotechnology UK. Papain and Bromelain were bought from
Sigma. Non-allergens Staphopain B (Biocentrum ltd, UK),
Calpain ll, Cathepsin B and C were purchased from Sigma. CPB
was kindly provided by Prof Jeremy Mottram, University of
Glasgow.
2.2.2 SDS polyacrylamide gel electrophoresis
(SDS- PAGE):
All protein preparations were analysed by electrophoresis using
12% Novex Tris-Glycine precast gels from Invitrogen. Tris
Glycine running buffer (TGS) was prepared (30.3g Tris, 144g
Glycine and 10g SDS made up to 1 L with water) and protein
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samples were run in XCell SureLock Mini-Cell from Invitrogen
under reducing conditions for 1hr 30mins at 125V. Samples
were diluted with 4X sample buffer (0.25M Tris-HCl pH 6.8, 8%
SDS, 30% Glycerol, 0.02% Bromophenol Blue and 0.3M DTT)
and heated to 95°C for 5 mins prior to loading. Protein
concentrations upon loading were 5µg per well; 5µl of a control
pre-stained protein ladder (Fermentas) was added to track
sample migration in the first lane of the gel.
2.2.3Western blot analysis:
After gel electrophoresis, nitrocellulose membranes
(Amersham, UK) were cut, soaked in Tris Glycine (TG blotting
buffer (25mM Tris pH8.5, 0.2M Glycine and 20% Methanol),
gel and membrane were assembled in an Invitrogen XCell II
Blot Module apparatus and soaked with 60 ml of TG blotting
buffer. The gels were then transferred for 1 hr at 30V. When
finished, the membranes were blocked overnight with 5% BSA
in TBS (0.05 M Tris-HCl, 0.15 M NaCl at pH 7.5) at 4°C. In the
glycan detection process, the DIG Glycan Differentiation Kit
(from Roche Applied Sciences, Germany) was used. The
membranes were washed twice with TBS and once with buffer
1 (TBS; 1 mM MgCl2, 1 mM MnCl2, 1 mM CaCl2 at pH 7.5). The
required amount of lectin solution was added (for GNA, SNA
and DSA 10 µl each; for MAA 50 µl and for PNA 100 µl) to 10
ml of buffer 1. All these lectins that are Digoxigenin (DIG
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labelled were incubated separately for 1 hr with the
membranes and the membranes were then washed three times
with TBS to remove any unbound antibodies. The secondary
antibody was prepared (10 µl of anti-DIG conjugated to
Alkaline phosphatase (diluted in 10 ml of TBS) and the
membranes were incubated with the antibody for one hour (Fig
2-1). The detection solution was prepared by using 10 ml
Buffer 2 (0.1 M Tris-HCl, 0.05 M MgC2, 0.1 M NaCl at pH 9.5)
diluted in 200 µl NBT/BCIP solution and the membranes were
then incubated with the detection solution for 20 mins in the
dark (Colorimetric detection). The reaction was stopped by
washing with ultra pure H2O. Membranes were scanned using
BioRad GS800 Densitometer. Positive and negative controls are
provided with the DIG Glycan detection kit and were used in
the western blot experiments.
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Table 2-1: The Lectins used to detect glycosylation in
allergens. All lectins were purchased from Roche Applied
Science, Germany.
The detection of 1,3 fucose was done using anti-1,3 fucose
rabbit polyclonal antibody (no. AS07 268, Agrisera, UK). This
antibody cross-reacts with fucose residues bound to N-Glycans
in alpha 1,3 in plants and insects. The concentration of
antibody used was 1µg/10ml of TBS buffer; the reaction
mixture was incubated for one hour then washed three times
with TBS buffer. Anti-rabbit antibody conjugated with
horseradish peroxidise (Sigma) was used as a secondary
antibody, again incubated for one hour, washed and the
reaction was detected using ECL chemiluminescent detection
reagent (GE Healthcare Life Sciences) according to
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manufacturers protocol. Membranes were scanned using
BioRad GS800 Densitometer. Bromelain was used as a positive
control and Cathepsin from mammalian origin was used as a
negative control
Fig 2-1: The principle of Colorimetric detection of
carbohydrates on allergens by Lectin binding.
2.2.4 Prediction of glycan structures in
allergens:
The oligosaccharide structures that are shown in this chapter
are symbolic representation suggested by the Consortium of
Functional Glycomics (www.functionalglycomics.org).
The structure codes comply with the proglycan system
(www.proglycan.com).
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2.3 Results:
2.3.1Detecting the pattern of N- and O-
glycosylation in allergens:
By using GNA, SNA, PNA, MMA and DSA labelled lectins and
anti-1,3 fucose antibody, allergens were scanned for the
different sugar moieties they possess. Der p 1, a cysteine
protease allergen from Dermatophagoides pteronyssinus,
reacted with GNA which recognises 1,2 1,3 and 1,6 mannose,
suggesting that it has high mannose N-glycans in its native
form (Fig 2-1 A). Der p 1 also showed a positive reaction with
1,3 fucose (Table 2-2), which indicates that it has part of the
CCD 1,3 fucose on its N-glycosylation site which is linked to
asparagine. It also reacted with DSA, PNA and SNA, which
respectively recognise 1,4 galactose, 1,3 galactose and sialic
acid linked 2-6 to galactose (Fig 2-2 A). Der p 1 failed to react
with MMA, thus suggesting that it does not contain any sialic
acid binding 2-3 to galactose.
When examining Papain, a cysteine protease allergen from
papaya, and Bromelain, a cysteine protease allergen from
pineapple, their glycosylation pattern was found to be similar
to that of Der p 1, and mannosylation seems to be the
dominant positive reaction in all these cysteine protease
allergens (Fig 2-2 B & D).
Chapter 2 Pattern of Glycosylation in allergens
44
The recombinant preparation of Der p 1 that is produced in
Pichia pastoris reacted with GNA to a higher degree than the
native preparation (Fig 2-2 C). The band itself was diffuse,
suggesting hyperglycosylation and its positive reaction with
GNA confirmed that most of the glycosylation is due to
mannosylation which is expected as proteins expressed in
yeast tend to be hypermannosylated (Jacquet et al., 2002,
Cereghino and Cregg, 2000, van Oort et al., 2002, Meno et al.,
2005, Staudacher et al., 1999). The preparation also reacted
with PNA suggesting that it also has some O-glycosylation
present as 1,3 galactose. The recombinant preparation does
not have any sialic acid or 1,4 galactose (Fig 2-2 C).
Fel d 1, the cat allergen Felis domesticus, is shown here to
have low levels of mannan with strong reactions also with DSA
and MAA, thus suggesting that it has 1,4 galactose and sialic
acid (Table 2-2). It does not, however, contain 1,3 fucose
which is expected as 1,3 fucose is not present in mammals (Fig
2-8 A). Its deglycosylated counterpart does not contain any
mannan, but it does contain sialic acid and 1,3 galactose
(Table 2-2). Can F 1 , the dog allergen Canis familiaris, is also
not fucosylated as it is from a mammalian source (Staudacher
et al., 1999, Altmann, 2007) (Fig 2-8 A), but it is
mannosylated and appears to contain sialic acid (Table 2-2).
The Brazilian nut allergen, Ber e 1, is mannosylated also and
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fucosylated (Table 2-2). The two allergens that showed a very
strong reaction with mannan, in addition to rDer p 1, were Ara
h 1 (Arachis hypogaea) and Bla g 2 (Blattella germanica).
These two allergens are highly mannosylated in their native
form which is indicated in Table 2-2.
Other major allergens such as Der p 2 failed to give a positive
reaction with GNA, indicating the lack of mannan in this
allergen (Fig 2-2 E). It did, however, react with 1,3 fucose (Fig
2-8 B) and also reacted positively with DSA, MMA, PNA and
SNA, which suggests that although lacking mannan, Der p 2 is
still glycosylated.
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Fig 2-2. Western blot analysis using different lectins that recognise specific
carbohydrate structures on allergens. Anti-GNA (recognises terminal mannose
-- + ++ +++ ++
A. nDer p 1
B. Papain
C. rDer p 1
D. Bromelain
E. Der p 2
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(13), (16) or (12) linked to mannose, anti-DSA recognises Gal-(14)GlcNAc
in complex, anti-MMA recognises sialic acid linked (23) to galactosee, anti-PNA
recognises the core disaccharide galactose (13) and anti-SNA recognises sialic
acid linked (26) to galactose. +++: strong reaction, ++: moderate reaction, +:
mild, --: no reaction, number of independent experiments 3.
Table 2-2: The table below shows the western blot results of
different lectin reactions with different allergens.
+++: strong reaction, ++: moderate reaction, +: mild reaction, --: no reaction,
number of independent experiments 3.
2.3.2Comparative studies of allergen and non-
allergen glycosylation patterns:
As mannosylation appears to be the dominant glycosylation
among allergens (Table 2-2), comparative carbohydrate
analysis was done for proteins that are not known to elicit
Allergen GNA (anti
mannose)
DSA MMA PNA SNA Anti-1,3 Fucose
nFel d 1 + + +++ - - -
DFel d 1 - - + ++ - -
Derp2 - + ++ +++ ++ +
Ara h 1 +++ - + ++ ++ ++
Bla g 2 +++ ++ + ++ ++ +++
Can f 1 + - + - ++ -
Ber e 1 + - ++ + ++ +
rDer p 1 +++ - - + - ++
Der p 1 + ++ -- ++ ++ +++
Papain ++ + - + + ++
Bromelain + + - ++ + +++
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allergic immune responses, yet share the same protein family
with allergens. The cysteine protease family includes Der p 1,
Papain and Bromelain as allergens and Staphopain B, Calpain
and Cysteine Protease B (CPB) as non-allergens (Bühling et al.,
2002, Smagur et al., 2009, Goll et al., 2003, Ghaemmaghami
et al., 2002, Oliver Schulz, 1998). All these proteins have
potent cysteine protease activity, but nothing is known about
their glycosylation pattern. Following experiments using GNA
lectin it became clear that the non-allergens Staphopain B and
Calpain do not react with GNA, thus indicating that they are
not mannosylated like allergens (Fig 2-3). Cysteine protease B
showed a very weak reaction with GNA, again indicating that it
has only a minimal amount of mannose moities. Staphopain B
also did not react with any of the other lectins, indicating that
it does not have any O-glycosylation. It did, however, give a
weak reaction with the 1,3 fucose antibody (Fig 2-9 B). Calpain
and CPB did react with PNA, MMA, SNA and DSA (Figs 2-4, 2-5,
2-6, 2-7), indicating the presence of O-glycosylation. These
two proteins also gave a weak positive reaction with 1,3 fucose
(Fig 2-9 B).
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Fig 2-3: Immunoblot of a cysteine protease family against GNA (Galanthus nivalis
agglutinin) which recognises terminal mannose, (13), (16) or (12) linked to
mannose. Cysteine proteases that are allergens: rDerp1, nDerp1, Bromalain and
Papain. Cysteine proteases that are non-allergens: Calpain II and Cysteine protease B
(CPB). Cysteine proteases that induce innate immunity: Staphopain B. 5Pgs of the
protein is loaded in each well. +++: strong reaction, ++: moderate reaction, +: mild
reaction, (+): weak reaction, --: no reaction, number of independent experiments=2.
Fig 2-4: Immunoblot of a cysteine protease family against PNA (Peanut agglutinin),
which recognises the core disaccharide galactose (13) N-acetylgalactosamine. +++:
strong reaction, ++: moderate reaction, +: mild reaction, (+): weak reaction, --: no
reaction, number of independent experiments=2.
Chapter 2 Pattern of Glycosylation in allergens
50
Fig 2-5: Immunoblot of a cysteine protease family against MMA (Maackia amurensis
agglutinin), which recognises sialic acid linked (23) to galactose. +++: strong reaction,
++: moderate reaction, +: mild reaction, (+): weak reaction, --: no reaction, number of
independent experiments=2.
Fig 2-6: Immunoblot of a cysteine protease family against SNA (Sambucus nigra
agglutinin), which recognises sialic acid linked (26) to galactose, thus in combination
with the data from lectin MMA which recognises sialic acid linked 2,3 to galactose (Fig
2-5), SNA is suitable for identifying sialylated glycan chains linked 2,6 to galactose on
proteins. +++: strong reaction, ++: moderate reaction, +: mild reaction, (+): weak
reaction, --: no reaction, number of independent experiments=2.
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Fig 2-7: Immunoblot of a cysteine protease family against DSA (Datura stramonium
agglutinin), which recognises Gal-(14) GlcNAc in complex and hybrid N-glycans in O-
glycans and GlcNAc in O-glycans. +++: strong reaction, ++: moderate reaction,
+: mild reaction, (+): weak reaction, --: no reaction, number of independent
experiments=2.
A. B.
Fig 2-8: Allergen and non-allergen reactions with fucose 1, 3 antibody. Der
p 1, rDer p 1, Bromelain, Papain, Ara h 1, Bla g 2 and Der p 2 are
fucosylated, but allergens derived from mammalian sources like Can f 1 and
Fel d 1 are not. The non-allergens cathepsin B and C are not fucosylated
(derived from bovine origin). +++: strong reaction, ++: moderate reaction,
+: mild reaction, (+): weak reaction, --: no reaction, number of independent
experiments=3.
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Fig 2-9: Comparative analysis between allergens and non-allergens, that
are cysteine proteases, in term of mannosylation and fucosylation.
Allergens are strongly mannosylated and have stronger reaction with 1,3
fucose compared to non-allergens. +++: strong reaction, ++: moderate
reaction, +: mild reaction, (+): weak reaction, --: no reaction, number of
independent experiments=2.
Allergens
Non
Allergens
A. Anti-Mannose
rDerp1 Derp1 Bromelain Papain Stap B Calpain CPB
rDerp1 Derp1 Bromelain Papain Stap B Calpain CPB
B. Anti- 1,3
Fucose
Chapter 2 Pattern of Glycosylation in allergens
53
2.3.3 Speculated structure of carbohydrates on
allergens:
The N-glycosylation structures in allergens were predicted with
the help of a symbolic representation suggested by the
Consortium of Functional Glycomics (Fig 2-10). The asparagine
linked structure is known to contain N-Acetylglucosamine
(GlcNAc). Data from this chapter showed that 1, 3 fucose is
present in Der p 1, in addition to 1, 3 and 1, 6 mannose (Fig 2-
10 A). In the literature, xylose was shown to be present in Der
p 1 and this information, together with those presented earlier,
would make it possible to predict how the sugar moieties are
arranged in this allergen. The recombinant Der p 1 preparation
reacted with fucose and mannose, and gave a stronger
reaction with high mannose, so it can be speculated that the
branching of mannose would be different than for native Der p
1. As rDer p 1 is expressed in yeast, it is highly likely that it
contains 1,2, 1,3 and 1,6 mannose (Fig 2-10 A). The higher
branching of mannose is expected to be 1,2 (Vervecken et al.,
2007) The high mannosylation of Ara h 1 and Bla g 2 is
expressed as more branching and the presence of 1,3 fucose is
stated (Fig 2-10 C). The structure of Papain and Bromelain is
already described in the literature, and their mannosylation
and fucylation was confirmed by western blot analysis (Fig 2-
10 B). What we know at the moment about the N-glycosylation
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of non-allergens is that they are not mannosylated which is
shown in Fig 2-10 (F). The fact that mammalian proteins do
not possess 1,3 fucose is shown also in Fig 2-10 (D & G).
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Fig 2-10: A speculated structure of N-glycosylation in some allergens
compared to mammalian N-glycosylation. Linkages and legends are
explained in the figure.
a
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2.4 Discussion:
Glycosylation in allergens is a key feature and mannosylation
seems to be the dominant glycosylation pattern with the
exception of Der p 2. Reports on glycosylation in Pichia
expressed proteins indicated that most of these proteins are
highly mannosylated (Cereghino and Cregg, 2000, Cereghino
et al., 2002, Meno et al., 2005), which is what this chapter
confirmed by using a GNA lectin that specifically binds to high
mannose structures. This work also demonstrated that Der p 1
is mannosylated in its natural form, which confirms what has
already been described in the literature using other methods of
glycan identification (Yang et al., 2008). In addition to Der p 1
we have also shown the predominance of mannan in the
glycosylation of other environmental allergens Ara h 1, Bla g 1,
Ber e 1, Can f 1, Fel d 1, Bromelain and Papain. Other groups
reported the presence of mannan in Cedar Allergen Cry j 1
(Aoki et al., 2010), pollen allergen Cha o 1 (Kimura Y, 2008),
yellow jacket allergen Ves v 2 (Seppälä et al., 2009) and
Ovalbumin (Plasencia et al., 2008). Ara h 1, Cor a 11, Jug r 2
and Ana o 1 have been reported to contain a xylose and
mannose in the N-glycan chain (Lauer, 2004, Kolarich and
Altmann, 2000). Fucose 1,3 is reported to be present in a wide
range of allergens like Hev b 1, Ara h 1, Bromelain and Papain
(Malik et al., 2008, van Ree et al., 2000, Altmann, 2007), and
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in this work we demonstrated for the first time that Der p 1,
rDer p 1 and Der p 2 contain fucose 1,3. This is important in
understanding the pattern of N-glycosylation in allergens, as
fucose 1,3 is not present in mammalian cells and as such is
considered non-self to humans. There is one report mentioning
the finding of xylose in Der p 1, which represents another
evidence for the presence of CCD in Der p 1 (Yang et al.,
2008)(Table 2-3). Cat (Fel d 1) and dog (Can f 1) allergens did
not have fucose 1,3 antibody which is expected as these two
allergens are derived from mammalian sources. In this
context, a speculative structure for N-glycosylation in different
allergens was depicted by combining the results of different
lectin antibody reactions with what has already been described
in literature regarding allergen N-glycosylation. A pattern has
emerged with major differences between allergens and their
non-allergen counterparts. The quality and quantity of
mannosylation and fucosylation between allergens like Der p 1,
Papain, Bromelain, Bla g 2 and Ara h 1 and non-allergens like
Cathepsin B, Cathepsin C, CPB, Calpain and Staphopain B is
different. A conclusion can be made that non-allergens possess
a very low quantity of mannose and fucose 1, 3. Previous
reports also mention that xylose 1,2 and xylose 1,3 are
present in some allergens like Papain, Ara h 1 and Bromelain
(Altmann, 2007, Shreffler et al., 2006, van Ree et al., 2000).
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The notion that Der p 1 and Der p 2 possess 1,3 fucose in their
native form provides a better understanding of their N-
glycosylation pattern.
The detection of galactose 1,3 galactose 1,4 and sialic acid in
allergens gave a better understanding of O-glycosylation in
allergens. Although most reports concentrate on N-
glycosylation as a target for lectin receptors on antigen
presenting cells, some recent reports did suggest that O-
glycosylation by itself plays a role in CCD (Commins and Platts-
Mills, 2010, Sandrine et al., 2009, Leonard R, 2005), which is
why it is important to know the specific structures of O-glycans
in allergens.
Table 2-3. N-glycans detected in Der p 1 (Yang et al., 2008).
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CHAPTER THREE: The expression of Der p
1 allergen in Pichia pastoris.
3.1 Introduction:
Der p 1 is a 25 kDa allergen with cysteine protease activity. It is
produced in the mid gut of the mite and found in mite faecal
pellets. It has been shown that up to 90% of individuals who are
sensitized to house dust mite allergens are actually responsive
to Der p 1 (Thomas and Smith, 1998, Burtin et al., 2009,
Richardson et al., 2005, Custovic et al., 1996, Spieksma FT,
1967).The molecular structure of Der p 1 has been the subject
of many studies. The gene encoding Der p 1 has been cloned
and sequenced, and the cDNA clone coding for Der p 1 was first
sequenced by Chua et al., (1988). It codes for a 222 residue
mature protein having a molecular weight of 25,371 and
containing four potential N-glycosylation sites. Der p 1 is
produced in the mite as enzymaticaly inactive proenzyme that
becomes active after cleavage of the propeptide. When Der p 1
is extracted from the mite faeces it is in the mature form (nDer
p 1) (van Oort et al., 2002, Chua et al., 1988, Meno et al.,
2005, de Halleux et al., 2006). Meno et al (2005) were able to
produce a recombinant form of Der p 1 that is hypoglycosylated
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using an N132E mutation that rendered the protein non-
susceptible to glycosylation at this site. The recombinant form
was expressed in Pichia pastoris.
Several groups produced recombinant forms for Der p 1 allergen
expressed in P. pastoris with full enzymatic and IgE binding
activity (Meno et al., 2005, de Halleux et al., 2006, Takai et al.,
2005, van Oort et al., 2002). The advantages of using P.
pastoris in expressing Der p1 is that it leads to a high level of
secretion; this system is also easy for fermentation to high cell
density and can be scaled up without losing any yield (Jacquet et
al., 2002). More importantly, this system lends itself to
modification of the expressed recombinant Der p 1 to produce
hyperglycosylated and hypoglycosylated forms using point
mutations and enzymatic deglycosylation. The four possible
glycosylation sites on Der p 1 are N16, N82, N132 and N 195;
by mutating these sites the degree of glycosylation can be
controlled in recombinant Der p 1 (Meno et al., 2005).
Recent work in our lab has shown that the uptake of Der p 1 by
the mannose receptor on dendritic cells is dependent on the
level of Der p 1 glycosylation. This clearly raises the question of
the role of glycans in allergen recognition and uptake by
dendritic cells, we therefore aimed to produce different
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glycoforms of Der p 1 through expressing it in Pichia pastoris,
which is reported to express Der p 1 in a hypermannosylated
form (Meno et al., 2005, de Halleux et al., 2006, Takai et al.,
2005, van Oort et al., 2002). We were also aiming to produce
different glyco-forms of Der p 1 that can be tested for
allergenicity.
3.2 Materials and Methods:
3.2.1 F'1$SXULILFDWLRQIURPǊSKDJHDQGǊ
phage 11 libraries:
ǊSKDJHDQGǊSKDJH OLEUDULHVNLQGO\SURYLGHGE\: R.
Thomas, Princess Margaret Children's Medical Research
Foundation, Perth, Australia) were used to obtain pro and
mature Der p 1 sequences. First, phenol/chloroform extraction
was done for both libraries to purify the cDNA which will
partition in to the aqueous layer and extract protein components
in to the organic phase.
The concentration of the cDNA for both libraries was measured
XVLQJWKHQDQRGURS1'VSHFWURSKRWRPHWHU,QǊSKDJH
the concentration for cDNA was 4101.3 ng/µODQGLQǊSKDJH
the concentration for cDNA was 3781.4 ng/µl.
3.2.2 Cloning of Pro and Mature Der p 1:
)URP WKH Ǌ SKDJH  DQG  OLEUDU\ of the house dust mite
Dermatophagoides pteroyssinus pro and mature Der p 1 cDNA
sequences products were amplified using Polymerase Chain
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Reaction (PCR). The reference for the primers used in amplifying
Der p 1 was van Oort et al., 2002. To facilitate cloning and
ligation, Kpnl restriction enzyme cutting site (GGT ACC) was
introduced to the 3 primer and Xhol 5 restriction enzyme
cutting site (GAG CTC ) was introduced to the 5 primer (Table
3-1).
It was noticed that the pPICZĮ A plasmid has a chain
termination sequence (TAA) that was introduced consequently
to the 3 primer. In order to make sure that the expression does
not stop before the C-terminal polyhistidine tag, as this will help
in purifying Der p 1 recombinant protein after expression, a
mutation was introduced to primer 4n.
PCR amplification for pro Der p 1 was done using primers
(4n+p1) and (4s+p1) (Table 3-1), while PCR amplification for
mature Der p 1 was done using primers (4n+p3) and (4s+p3)
(Table 3-1). The PCR reaction was carried out in a volume of 25
µl containing 1 µg of cDNA template. The reaction conditions
were as follow: initial denaturation at 94qC for 10 mins followed
by 5 cycles of denaturing at 94qC for 90 mins, annealing at 50qC
for 90 mins and extention at 72qC for 4 mins. Then another 5
cycles of denaturating at 94qC for 90 mins, annealing at 55qC for
90 mins and extention at 72qC for 4 mins and a final 25 cycles of
denaturing at 94qC for 90 mins, annealing at 60qC for 90 mins
and extention at 72qC for 4 mins.The reaction final extension
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was at 72qC for 20 mins.Then they were run on 0.8% e. gels for
detection.
Table 3-1: Primers used to obtain Der p 1 cDNA by PCR.
3 primers
To amplify mature and pro Der p
1 with kpnI restriction digestion
(with no stop codon) (4n)
5GGG GGT ACC TTG AGA ATG ACA
ACA TAT GG 3
To amplify mature and pro Der p
1 with kpnI restriction digestion
(with a stop codon) (4s)
5GGG GGT ACC TTA GAG AAT GAC
AAC ATA TGG 3
To amplify mature and pro Der p
1 with xhol restriction digestion
site (with a stop codon) (p2)
5 GGG GAG CTC TTA GAG AAT GAC
AAC ATA TGG 3
5 primers
To amplify pro Der p 1 with
xhol restriction digestion (p1)
5GGG CTC GAG AAA AGA CGT
CCA TCA TCG ATC AAA ACT TTT G
3
To amplify mature Der p 1 with
xhol restriction digestion (p3)
5 GGG CTC GAG AAA AGA CGT
CCA TCA TCG ATC AAA ACT ATG 3
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Table 3-2: Primers used for sequencing (from Invitrogen).
Primer Sequence
5´ AOX1 sequencing primer
(5´ Pichia primer)
5´-GACTGGTTCCAATTGACAAGC-3´
3´ AOX1 sequencing
primer (3´ Pichia primer)
5´-GCAAATGGCATTCTGACATCC-3´
D-Factor sequencing
primer
5´-TACTATTGCCAGCATTGCTGC-3´
3.2.3 Purification of Der p 1 PCR product:
The PCR products for the pro and mature Der p 1 were purified
using QIAquick PCR purification kit according to manufacturer
protocol, and its concentrations were measured using the
nanodrop ND 1000 spectrophotometer, then the product was run
on agarose 2% e-gel for detection.
3.2.4 Sequencing mature and pro Der p 1 PCR
product:
Sequencing reaction using Big Dye v1.1 was done according to
the following conditions: denaturing at 96qC for 30 sec,
annealing at 50qC for 15 sec and extention at 60qC for 4 mins,
then a final extention at 28qC for 1min.
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Then samples were precipitated by ethanol precipitation and
sequenced using the ABI 3130 analyser to confirm that the PCR
products are for the cDNA of mature and pro Der p 1.
Comparison alignment for the amplified PCR product of the
mature and pro Der p 1 with gene bank data for the complete
Der p 1 allergen was done using the Blast search engine to
detect compatibility.
3.2.5 Transformation of pro and mature Der p 1
insert in to TOP 10 E. coli cells:
Double restriction enzyme digest reaction was carried out for
both pPICZ Į A plasmid and Der p 1 inserts using Kpn I and Xho
I restriction digest enzymes (from Invitrogen). For Der p 1
inserts 10 U of Kpn I were used in the first digest with 2.5 µl
REact® 4 enzyme buffer from Invitrogen and up to 0.49ug of
the Der p 1 DNA product then distilled water was added to have
a final reaction mixture of 25 µl. This mixture was incubated at
37qC for 1 hour then deactivated at 80qC for 20 mins. After that
another digest using 10 U of Xho l was carried out for another 1
hour at 37qC. The same conditions were used to digest 0.5µg of
pPICZ Į A plasmid. After deactivation of the reaction at 80qC
both the plasmid and Der p 1 inserts were purified using
Quiagen purification kit and its concentrations were measured
using the nanodrop ND 1000 spectrophotometer. Then, the PCR
product of pro and mature Der p 1 was ligated to pPICZ Į A
Chapter 3 Expression of Der p 1
66
Vector using Ready-To-Go T4 DNA ligase kit according to
manufacturer protocol. Different molar ratios (1:4, 1:7, 1:10
and 1:20) for vector against insert were used to optimise the
ligation reaction. Then TOP 10 E. coli chemically competent cells
(from Invitrogen) were used to transform pPICZ Į A vector.
Competent cells were kept chilled on ice during transformation,
up to 35.0 ng of DNA (Plasmid with Insert) in 10 µl volume was
mixed with 80 µl competent cells. For the positive control 9.0 ng
of pPICZ Į A was mixed with 80 µl competent cells while for
negative control no vector was added to the competent cells. All
mixtures were immediately placed on ice for 30 minutes then
they were heat shocked at 42qC for 45 sec then 900 µl of LB
media was added to the mixtures and incubated for 1 hr at
37qC. The reaction was then plated on LB Zeocin plates
overnight at 37qC. Colonies that grew overnight were detected
by PCR using the D-Factor sequencing primer and 3´ AOX1
sequencing primer to check for the plasmid. The PCR reaction
conditions were as follow: initial denaturation at 94qC for 10
mins followed by 35 cycles of denaturing at 94qC for 90 mins,
annealing at 54qC for 90 mins and extension at 72qC for 2 mins
and a final extension at 72qC for 2 mins. The plasmid used was
purified from the E. coli culture using PurLink Quick Plasmid
Miniprep kit according to manufacturer protocol, then it was
sequenced using Big Dye v1.1 sequencing reaction as follow:
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denaturing at 96qC for 30 sec, annealing at 50qC for 15 sec and
extention at 60qC for 4 mins for 25 cycles, then a final extention
at 28qC for 1min. Only colonies having the Der p 1 insert ligated
with the plasmid were selected, streaked and then grown in LB
Zeocin culture overnight at 37qC.
3.2.6 Transformation of pro and mature Der p 1
insert in to X33 yeast competent cells:
Competent cells from X33 yeast cell culture (provided in the
easyComp kit from invitrogen) were prepared acoording to
manufacturer protocol.The plasmid used was linearized using
SacI restriction digest at 37qC for 2 hours using 5.0 U of Sac I to
digest 5 µg of plasmid DNA. Buffer 1 was added to the reaction
provided from New England BioLabs. Then up to 5 µg of the
linearized plasmid was transferred to Pichia pastoris X33
competent cells using the EasyComp transformation kit from
invitrogen according to the kit protocol. Positive and negative
controls were introduced during transformation reaction. After
that Pichia cells were plated on YPD Zeocin containg media at
30°C for 2 days and the colonies that were growing were
detected for the insert again by PCR using the D-Factor
sequencing primer and 3´ AOX1 sequencing primer, then
colonies having the plasmid were chosen to express Der p 1 in a
fermentor system containg methanol. The expressed protein was
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purified using His Tag purification protocol and analysed by SDS-
polyacrylamide gel electrophoresis.
3.2.7 Expression of recombinant Der p 1 in Pichia
pastoris cells:
Single colonies of Pichia Cells having Der p 1 insert in them
were streaked on YPD media and incubated for 2 days at 30°C.
A single colony was inoculated in 5ml BMGY media in 50ml tube,
grown at 30°C in a shaking incubator at 250 RPM until the
culture reached an OD of 2-6 at 600nm. Cells were then
harvested at 3000 g for 5 mins at RT, supernatant was removed
and cell pellet was resuspended in BMMY media to an OD600 of
1.00 and methanol was added every 24hrs to induce expression.
At different time points, 1 ml of the expression media was taken
for analysis (Before Induction, 5mins, 30mins, 1hr, 2 hrs, 4hrs,
24 hrs, Day2, Day3 and Day4) to determine the optimal time
post-induction to harvest. Samples were kept at -80 until
analysis.
3.2.8 Trichloroaceticacid (TCA) precipitation:
In order to concentrate the protein samples, they were
precipitated by TCA. Supernatant samples were filter sterilized,
then one volume of 100% TCA was added to 4 volumes of
protein sample. The mixture was incubated at 4°C for 15 mins,
centrifuged at 4000g, supernatant was removed and protein
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pellet was washed with cold acetone twice. Pellet was dried at
95°C for 10 mins, then prepared for SDS-PAGE analysis.
3.2.9 Ammonium sulphate sample concentration:
This procedure is useful to fractionate a mixture of proteins.
Since large proteins tend to precipitate first, small ones will stay
in the solution, thus by analyzing various salt fractions we can
find the conditions where the protein we are studying
precipitates, and this will increase the purity of protein of
interest. A saturated solution of 4.00 M ammonium sulphate was
prepared and filter sterilized. Ammonium sulphate was slowly
added to cold protein solution while gently mixing until 10%
saturation is reached. Samples were incubated for 20 mins on
ice with occasional mixing, then the samples were centrifuged
and the pellet was collected. More ammonium sulphate was
added to the supernatant to reach 20%, 30% and 40%
saturation and the pellet was collected from each fraction. Those
fractions from each protein preparation were resuspended in
suitable buffer and dialyzed and stored for further purifications.
3.2.10 SDS polyacrylamige gel electrophoresis
SDS-PAGE:
Cell supernatants were analyzed by electrophoresis using
precast 12% PA gels from Invitrogen, tris glycine running buffer
(TGS) was prepared and protein samples were run under
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reducing conditions for 1hr 30mins at 125V. Protein
concentrations on loading were in the range of 5µg to 10 µg.
3.2.11 Coomassie staining analysis:
Gels were washed with deionised H2O and stained with
Coomassie brilliant blue Imperial ready to go stain from
Invitrogen for 1hr, they were then destained overnight with H2O
according to the manufacturer protocol.
3.2.12 Silver staining analysis:
Silver staining is a more sensitive tool for protein visualization
providing a detection level down to 0.25 ng of protein. The
protein detection depends on silver ions binding to amino acid
chains of proteins followed by the reduction of these ions giving
a metallic silver stain on the gel. Gels were stained using the
Dodeca silver staining kit from Biorad according to the
manufacturers protocol.
3.2.13 Western blot analysis:
After gel electrophoresis, nitrocellulose membranes (Amersham,
UK) were cut, soaked in tris glycine blotting buffer, gel and
membrane were assembled in an Invitrogen transblot apparatus
and soaked with blotting buffer according to the manufacturers
protocol. The gels were transferred for 1 hr at 30V. When
finished they were blocked overnight with 5% BSA in TBS Tween
at 4°C, then incubated for 1 hr with anti-Der p 1 (5H8)
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antibody, washed and incubated with anti-mouse secondary
antibody conjugated with alkaline phosphatase (AP) and then
detected with AP chromogen (NBT-BCIP® solution from Sigma)
for 1 hr. After that the reaction was stopped by washing with
ultra pure H2O.
3.2.14 Mutation of Der p 1 glycosylation sites:
The Pro-Der p 1 sequence has 4 possible mutation sites (N16,
N82, N132 and N195) (Figs 3-1 & 3-2). Using Stratagene
QuikChange® Primer Design program (http://www.stratagene
.com/sdmdesigner/default.aspx), primers were designed to
change AAC (ASP) Asparagine to CAA (Gln/Q) or Glutamine CAG
(Gln/Q) Glutamine in all four mutation sites (Table 3-3).
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Table 3-3: Primers used in producing site directed
mutations in the glycosylation sites of Wild Type Der p 1
Amplicon.
N16
Forward N16
5'-ttttgaagaatacaaaaaagccttccagaaaagttatgctaccttcgaagatg-3'
Reverse N16
3'-aaaacttcttatgttttttcggaaggtcttttcaatacgatggaagcttctac-5
N82
Forward N82
5'-caaaactcaattcgatttgaatgctgaaactcaggcctgcagtatcaatg-3'
Reverse N82
3'-gttttgagttaagctaaacttacgactttgagtccggacgtcatagttac-5'
N132
Forward N132
5'-atcagcttatttggcttaccgtcagcaatcattggatcttgctgaac-3'
Reverse N132
3'-tagtcgaataaaccgaatggcagtcgttagtaacctagaacgacttg-5'
N195
Forward N195
5'-cacaacgtttcggtatctcacagtattgccaaatttacccacc-3'
Reverse N195
3'-gtgttgcaaagccatagagtgtcataacggtttaaatgggtgg-5'
Fig 3-1: diagram of glycosylation sites in pro Der p 1 DNA
sequence.
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Fig 3-2: Glycosylation sites in pro Der p 1 DNA sequence.
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3.2.15 The Quick change site directed mutagenesis
method:
Using Stratagene QuikChange® kit DNA plasmids containing
N16, N82, N132 and N195, mutants were denatured, the
mutagenic primers annealed and extended with PfuUltra DNA
polymerase (Fig 3-3), the parental plasmid were digested with
DpnI and all plasmids were transformed to TOP 10 E. coli
competent cells, separately. Some colonies were selected for
sequencing to detection of the desired mutation. Plasmids were
then propagated and purified from E. coli cells using PureLink
Quick plasmid Miniprep Kit according to manufacturer protocol.
Fig 3-3: The Quick change site directed mutagenesis method.
The PCR reaction conditions were as follow:
5 ǋl of 10× reaction buffer
2 ǋl (10 ng) of pWhitescript 4.5-kb control plasmid (5 ng/ǋl)
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1.25 ǋl (125 ng) of oligonucleotide control primer #1
1.25 ǋl (125 ng) of oligonucleotide control primer #2
1 ǋl of dNTP mix
38.5 ǋl ddH2O (to bring the final reaction volume to 50 ǋl)
Then add
1 ǋl of PfuUltra HF DNA polymerase (2.5 U/ǋl)
Segment Cycles Temperature Time
1X
95°C 30 seconds
25x
95°C 30 seconds
55°C 1 minute
68°C 13mins
1 ǋl of the Dpn I (10 U/ǋl) restriction enzyme was added
directly to each amplification reaction and digest at 37° C for 1
hr. Cells were transformed to E.coli TOP 10 Competent cells.
3.2.16 Sequence analysis and alignments:
Sequencing reactions using Big Dye v1.1 were done according to
the following conditions: denaturing at 96qC for 30 sec,
annealing at 50qC for 15 sec and extension at 60qC for 4 mins,
then a final extension at 28qC for 1min.
Then samples were precipitated by ethanol precipitation and
sequenced using the ABI 3130 analyser to confirm that the PCR
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products were for the cDNA of pro-Der p 1. Sequence analysis to
confirm mutations in the glycosylation sites for Der p 1 was also
done. Comparison alignment for the mutants to the wild type
Der p 1 was done using the Blast search engine to detect site
mutations (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Table 3-4: primers used to sequence Wild Type Der p 1 and
mutants to detect differences.
Primer Sequence
5´ AOX1 sequencing primer
(5´ Pichia primer)
5´-GACTGGTTCCAATTGACAAGC-3´
3´ AOX1 sequencing primer
(3´ Pichia primer)
5´-GCAAATGGCATTCTGACATCC-3´
D-Factor sequencing primer 5´-TACTATTGCCAGCATTGCTGC-3´
3.2.17 Transformation of N16, N82, N132 and N195
Der p 1 mutants to TOP 10 E. coli competent
cells:
TOP 10 E. coli chemically competent cells (from Invitrogen) were
used to transform N16, N82, N132 and N195 Der p 1 mutants in
pPICZ Į A vector. Competent cells were kept chilled on ice
during transformation, and up to 40.0ng of DNA (Plasmid with
Insert) in 10 µl volume was mixed with 80 µl competent cells.
For the positive control, 10.0 ng of pPICZ Į A was mixed with 80
µl competent cells, while for the negative control no vector was
added to the competent cells. All mixtures were immediately
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placed on ice for 30 minutes, then they were heat shocked at
42qC for 45 sec, then 900 µl of LB media was added to the
mixtures and incubated for 1 hr at 37qC. The reaction was then
plated on LB Zeocin plates overnight at 37qC. Colonies that grew
overnight were detected by PCR using the D-Factor sequencing
primer and 3´ AOX1 sequencing primer to check for the plasmid.
The PCR reaction conditions were as follow: initial denaturation
at 94qC for 10 mins, followed by 35 cycles of denaturing at 94qC
for 90 mins, annealing at 54qC for 90 mins and extension at
72qC for 2 mins and a final extension at 72qC for 2 mins. Only
colonies having the Der p 1 insert were selected, streaked and
then grown in LB Zeocin culture overnight at 37qC.
3.2.18 Purification of plasmid from E.coli TOP 10
culture:
Purification of N16, N82, N132 and N195 pPICZ Į A vector from
E. coli TOP 10 culture was done using PureLink Quick plasmid
Miniprep Kit according to manufacturers protocol. The
concentration of plasmid was measured with the nanodrop ND
1000 spectrophotometer. The purified plasmid was then run on a
2% agarose e-gel to confirm its purification and it was
sequenced to ensure that it is the pPICZ Į A vector. All plasmids
were then sequenced using Big Dye v1.1 sequencing reaction to
confirm the correct mutation in the Der p 1 sequence.
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3.2.19 Transformation of pro and mature Der p 1
insert in to X33 yeast competent cells:
Competent cells from X33 and GS115 yeast cell culture
(provided in the easyComp kit from Invitrogen) were prepared
acoording to manufactorer protocol.The plasmid used was
linearized using SacI restriction digestion at 37qC for 2 Hours
using 5.0 U of Sac I to Digest 5 µg of plasmid DNA. Buffer 1 was
added to the reaction provided from New England BioLabs. Then
up to 5 µg of the linearized plasmid was transferred to Pichia
pastoris X33 and GS115 competent cells using the EasyComp
transformation kit from invitrogen according to the kit protocol.
Positive and negative controls were introduced during
transformation reaction. After that Pichia cells were plated on
YPD Zeocin containg media at 30°C for 4 days and the colonies
that were growing were detected for the insert again by PCR
using the D-Factor sequencing primer and 3´ AOX1 sequencing
primer, then colonies having the plasmid were chosen to express
Der p 1 in a fermentor system containg methanol.
3.2.20 Expression of different glycoforms in Pichia
pastoris X33 and GS115 cells:
Using a single colony, 5 ml BMGY (Buffered Glycerol-complex
Medium) media were inoculated in a 50 ml tube, and grown at
2830°C in a shaking incubator (250300 RPM) until culture
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reaches an OD600 = 2 (the OD recommended by Invitrogen is
2-6). Such cells will be in early log-phase growth. Cells were
then harvested by centrifuging at 1,5003,000 g for 5 minutes
at room temperature. Supernatant was then decanted and cell
pellet was resuspended to an OD600 of 1.0 in BMMY (Buffered
Methanol-complex Medium) to induce expression.
At each of the time points (before Induction, 5mins, 30mins,
1hr, 2 hrs, 4hrs, 24 hrs, Day2, Day3 and Day4), 1 ml of the
expression culture was transferred to a 1.5 ml microcentrifuge
tube. These samples were used to analyze expression levels and
determine the optimal time post-induction to harvest.
Supernatants were then transferred to a separate tube and
stored at 80°C until ready to assay. Analysis by silver staining
and western blot was made for Der p1 expression.
3.3 Results:
3.3.1 PCR amplification for the cDNA of Mature and
pro Der p 1:
Phenol/chloroform extraction was done for both libraries to
SXULI\WKHF'1$,QǊSKDJHWKHFRQFHQWUDWLRQIRUF'1$ZDV
4101.3 ng/µODQGLQǊSKDJHWKHFRQFHQWUDWLRQIRUF'1$ZDV
3781.4 ng/µl.
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Mature and pro Der p 1 sequences were amplified by PCR using
the primers listed in table 1. They were run on 0.8% agarose e-
gel for detection (Fig 3-4).
3.3.2 Purification of Der p 1 PCR product:
The PCR products for the pro and mature Der p 1 were purified
using QIAquick PCR purification kit according to manufacturer
protocol, and its concentrations were measured using the
nanodrop ND 1000 spectrophotometer (Table 3-5), then the
product was run on agarose e-gel for detection (Fig 3-5).
Fig 3-4: amplification of pro and mature 'HU S  IURP Ȝ SKDJH  OLEUDU\.
Ladder: 1 Kb plus DNA ladder, well 1-2: amplified pro Der p 1 using primers
(4n+p1), well 3-4: amplified pro Der p 1 using primers (4s+p1), well 5-6:
amplified mature Der p 1 using primers (4n+p3), and well 7-8: amplified mature
Der p 1 using primers (4s+p3).
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Table 3-5: Der p 1 purified PCR product concentrations.
Purified PCR Sample Concentration ng/µl
PCR Sample 1 (pro Der p 1 ) 15 ng/µl
PCR Sample 2 (pro Der p 1 ) 37.7 ng/µl
PCR Sample 3 (pro Der p 1 ) 38.1 ng/µl
PCR Sample 4 (pro Der p 1) 33.3 ng/µl
PCR Sample 5 ( mature Der p 1) 49.3 ng/µl
PCR Sample 6( mature Der p 1) 38.9 ng/µl
PCR sample 7( mature Der p 1) 27.2 ng/µl
PCR sample 8( mature Der p 1) 29.0 ng/µl
Sequencing mature and pro Der p 1 PCR product:
Sequencing for mature and pro PCR products was done using the
ABI 3130 analyser was used to confirm that the PCR products are
for the cDNA of mature and pro Der p 1. Comparison alignment for
the amplified PCR product of the mature and pro Der p 1 with gene
Fig 3-5: PCR product run on gel after purification. Well 1: 1 Kb plus
DNA ladder. Well 3- 6: Purified PCR samples for pro Der p 1. Well 7-
10: Purified PCR samples for mature Der p 1.
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bank data for the complete Der p 1 allergen shows compatibility
(Figs 3-6, 3-7).
Fig 3-6: Sequencing results for the mature Der p 1 PCR
product.
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Fig 3-7: Comparison alignment for the amplified PCR
product of the mature Der p 1 with gene bank data for the
complete Der p 1 allergen shows compatibility.
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3.3.3 Ligation of pro and mature Der p 1 PCR insert
in pPICZ Į A vector:
The purified PCR product of pro and mature Der p 1 was ligated
to pPICZ Į A Vector (Fig 3-8). First, restriction digestion using
KpnI and Xho I was done for both the PCR product and pPICZ Į
A vector, then the ligation reaction was carried out for Der p 1
and pPICZ Į A vector using Ready-To-Go T4 DNA ligase kit
according to manufacturer protocol.
3.3.4 pPICZ Į A Vector (with pro and mature Der p
1 insert) transformation into E. coli:
By using chemically competent TOP 10 E. coli cells the plasmid
was transferred using chemical transformation method. Positive
Fig 3-8: pPICZ Į A vector with mature
Der p 1 insert in. (Diagram drawn by
MacVector program Ver.7)
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and negative controls were used during transformation (Fig 3-
9). In order to detect if pro and mature Der p 1 insert is ligated
to the plasmid in the transformed colonies, a PCR reaction was
made using primers close to Der p 1 Insert location in the
plasmid to amplify a piece of the plasmid with Der p 1 insert in it
(Fig 3-10).
A. B.
C. D.
Fig 3-9: Chemical transformation of pPICZĮ A vector with Der p 1 insert in
TOP 10 E.coli. A. positive control for pPICZĮ A vector transformation with no
insert. The plate shows many colonies B. negative control (no plasmid), C and
D Chemical transformation of pPICZĮ A with Der p 1 insert in TOP 10 E.coli.
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Fig 3-10: Map for primers location in pPICZ Į A vector. (Diagram
drawn by MacVector program Ver.7)
3.3.5 Detection of Der p 1 insert in transformed
TOP 10 E. coli colonies:
In order to detect if pro and mature Der p 1 insert is ligated to
the plasmid in the transformed colonies, before tranforming this
plasmid to yeast cells, a PCR reaction was made using primers
close to Der p 1 insert location in the plasmid to amplify a piece
of the plasmid with Der p 1 insert in it. By using the D-Factor
sequencing primer and the 3´ AOX1 sequencing primer (Table
3-6), a PCR fragment of 918 bp should appear on the gel if the
Der p 1 insert is in, if it is not in, the PCR fragment should be
266 bp (Fig 3-11).
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Table 3-6: primers used to detect Der p 1 insert in pPICZ Į A vector
Primer Sequence
5´ AOX1 sequencing primer (5´
Pichia primer)
5´-GACTGGTTCCAATTGACAAGC-3´
3´ AOX1 sequencing primer (3´
Pichia primer)
5´-GCAAATGGCATTCTGACATCC-3´
D-Factor sequencing primer 5´-TACTATTGCCAGCATTGCTGC-3´
The presence of mature (Wells 3, 4, 6, 7 and 11 in figure 3-11
B) and pro Der p 1 (Well 10 and 11 in Figure 3-11) was
confirmed by sequencing those PCR fragments using the ABI
A.
B.
Fig 3-11: PCR amplification of pPICZ Į A plasmid from E. coli TOP 10 transformed
colonies. Figure A: Well 1 : 1 Kb plus DNA ladder. Well 2-9, 12: PCR amplification for
colonies having pPICZĮ a plasmid with no pro Der p 1 insert (266 bp) . Well: 10-11: PCR
amplification for colonies having pPICZĮ a plasmid with pro Der p 1 Insert (up to 1000
bp). Figure B: Well 1: 1 Kb plus DNA ladder. Well 2, 5, 8, 9: PCR amplification for
colonies having pPICZĮ a plasmid with no mature Der p 1 insert (266 bp). Well 3, 4, 6, 7,
11: PCR amplification for colonies having pPICZĮ a plasmid with mature Der p 1 Insert
(918 bp).
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3130 analyser and comparing sequences with plasmid and Der p
1 sequenced data.
Only the colonies having the mature and proDer p 1 insert were
streaked on LB media Zeocin selective plates, then pure colonies
were cultured overnight in LB zeocin selective media in a
shaking incubator at 37qC.
3.3.6 Purification of plasmid from E.coli TOP 10
culture:
Purification of pPICZ Į A vector from E. coli TOP 10 culture was
done using PureLink Quick plasmid Miniprep Kit according to
manufacturer protocol. The concentration of plasmid was
measured with the nanodrop ND 1000 spectrophotometer. The
purified plasmid was then run on 2% agarose e-gel to confirm
its purification and it was sequenced to assure that it is pPICZ Į
A vector (Fig 3-12).
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3.3.7 Transformation to X33 yeast competent cells:
By using chemically competent X33 yeast cells, the purified
linear plasmid was chemically transformed to yeast cells and
plated on YPD Zeocin agar plates. The plates were incubated at
30ºC for 2 days. The cells that grew were detected for the pPICZ
Į A vector using PCR. Colonies detected by PCR having the
plasmid in were chosen to express Der p 1 in methanol
fermentation system (Fig 3-13).
A.
B.
Fig 3-12: A. Concentration of purified pPICZ Į A
vector from E. coli culture. B. Well 2: 1 Kb plus DNA
ladder. Well 5: purified pPICZ Į A vector from E. coli
culture.
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A. B.
C. D.
Fig 3-13: Chemical transformation of pPICZĮA with Der p 1
insert to X33 chemically competent cells. A. positive control for
pure pPICZĮ A vector transformation with no insert. B. negative
control C and D Chemical transformation of pPICZĮ A with Der p
1 insert in X33 yeast cells.
3.3.8 Expression of rDer p 1 in Pichia pastoris X33
and GS115 yeast cells:
Der p 1 was expressed in yeast cells and detected by western
blot against anti-Der p 1 (5H8). A band that reacted with 5H8
could be detected at 25 kDa in the culture after 4 days of
induction. It was also noticed that a diffuse band of a MW
between 50 and 100 kD appeared after 5 mins of methanol
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induction then dissociated after day 1 of induction. In the same
culture in day 1,there was also a major band at 40 kD after 4
hrs of induction (Fig 3-14 A)and another band at 25 kD also
reacted with 5H8 suggesting expression of Der p 1 might be of
different glycosylation forms by the yeast cells (Fig 3-14 A) or
that the culture proteases are affecting the expression. These
results were inconsistent and could not be repeated. In Fig 3-14
(B) another expression of a different colony can be detected.
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A.
B.
Fig 3-14: Time point expression of WT Der p 1 (pro Der p 1) and
mature Der p 1 in Pichia pastoris cells before and after methanol
induction to induce expression. This is a western blot against
anti Der p 1 5H8 for two separate experiments of expression (A
and B).
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3.3.9 Mutagenesis of the glycosylation sites in Der
p 1 amplicon:
Quick change site directed mutagenesis method was used to
construct point mutations in N16, N82, N132 and N195 Der p 1
glycosylation sites. The new plasmids were transferred to TOP
10 cells and the colonies that grow at 37°C were streaked,
single colonies were chosen from the plate, cultured in LB media
ON at 37°C and the plasmids were purified from the culture ran
on a gel then sequenced and aligned to the wild type unchanged
plasmid to confirm mutagenesis. It was found that all four
Asparagine residues in four plasmids were changed to Glutamine
by changing ACC to CAG (Figs 3-15, 3-16, 3-17, 3-18).
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N16
N82
N132
N195
Fig 3-15: Sequence alignment comparisons of Site mutations (N16,
N82, N132, N195) in Der p 1 insert compared to wild type.
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Fig 3-16: The whole sequence of N82 Der p 1 compared to the
Wild Type Der p 1.
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Fig 3-17: Purified fractions of mutant Der p 1 plasmids (N16,
N82, N132 and N195) ran on 2% e. gels to detect pure
plasmids.
A. B.
C. D.
Fig 3-18: Purified fractions of mutant Der p 1 plasmids
measured by the nanodrop. A. N16; B. N82; C. N132; D. N195.
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3.3.10 Plasmids N16, N82, N132 and N195
transformation to X33 competent Pichia cells:
Plasmids having Der p 1 insert with mutants in each of its
glycosylation site were concentrated and transformed to X33
competent Pichia. Colonies were grown for 4 days at 30° C;
positive and negative controls were introduced to monitor
transfer. For the positive control the uncut pPiczĮA was used and
no vector was used with the negative control (Fig 3-19).
A. B. C.
D. E. F.
Fig 3-19: Chemical transformation of pPICZĮA with Der p 1
inserts [(A) Wild Type, (B) Positive control the uncut pPiczĮA
with no Der p 1 insert and (C-F) mutants] to X33 chemically
competent cells.
3.3.11 Expression of different glycoforms in Pichia
cells:
All four Der p 1 mutants were expressed in yeast cells. Cells
were cultured in BMGY media as a starter culture, then to induce
expression they were transferred to BMMY media with continual
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induction by methanol for four days at 30°C. Cultures were then
harvested and prepared for detection of expression. Both 5H8
and 2C7 anti-Der p 1 antibodies were used to detect expression
(Fig 3-20).
It was noticed that the different Der p 1 mutants expressed at
25 kDa indicating aglycosylation.
Ƨ.
ƨ.
Fig 3-20: Immunoblot against anti-Der p1 (5H8) showing the
expression of Der p 1 glycoforms in X33 and GS115 yeast cells
(Ƨ and ƨ).
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3.4 Discussion:
Der p 1 is a cysteine protease allergen that is recognised as
being one of the most potent indoor allergens (Altmann, 2007,
Adnan et al., 1996, Charbonnier et al., 2003, Deb et al., 2007,
Ghaemmaghami et al., 2002, Shakib et al., 1998).
In this work, the Der p 1 cDNA PCR product was successfully
amplified from a phage library, sequenced, inserted into a
vector, transformed to TOP 10 cells for amplification and
concentration. The vector was then purified, concentrated,
transformed to yeast X33 competent cells and expressed.
Mutants of possible glycosylation sites in the proDer p 1
amplicon were produced using quick-change site directed
mutagenesis kit. The four plasmids having those mutants were
then sequenced, transformed to TOP 10 cells then purified,
concentrated, transformed to yeast X33 competent cells and
expressed.
Der p1 and four deglycosylated mutants (N16, N82, N132,
N195) were successfully expressed in Yeast as shown by their
reaction to anti-Der p 1 5H8. However, the expressed protein
glycosylation profile in yeast cells seem to be controlled by
multiple factors. Methanol induction, carbon source and growth
conditions of the cells are major factors that control the degree
of glycosylation of expressed proteins in Pichia. A high molecular
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weight form of Der p 1, indicating hyperglycosylation, was
detectable on the first day of expression after inducing the cells
with methanol. A major band at 40 kD is visible in well 7 of
figure 3-14, which is thought to be the expressed recombinant
Der p 1. However, on subsequent days of expression, a 25kDa
protein band appeared in the culture and the other bands
disappeared. This may suggest that the expressed protein is
affected by the culture proteases and thus should be harvested
at an early stage of expression. The issue of protease
degradation in yeast expression systems have been reported in
literature; they are thought to be a result of methanol induction
and high cell density which triggers excess protease production
and cell lysis (Zhang et al., 2007, Sinha et al., 2005). Other
optimisation measures in culture conditions are needed if we
were to have a consistent hyperglycosylated form. It was
reported that the glycosylation of expressed protein in Pichia
could be controlled via the pH of the medium in addition to
controlling the cell density and methanol concentration (Liu H
2005).
In parallel to the expression of the wild type, different
mutations to Der p 1 cDNA were done for the glycosylation sites
to try and produce different glycoforms. The newly produced
glycoforms were assessed by western blot and they all had a 25
kD molecular weight indicating that there was no variation in the
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glycosylation pattern and that the factors controlling the
production of different glycoform of Der p 1 in Pichia are variable
and not dependent only on mutating the glycosylation sites
alone. The hyperglycosylated form itself was very difficult to be
expressed again thus it could not be purified.
As the main aim of expressing Der p 1 was not only to produce
different glycoforms but also to have enough quantity of each to
get some readouts regarding immune recognition it was a
necessity that different methods with more consistent results be
introduced to produce the glycoforms from allergens, which
chapter four focused on.
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CHAPTER FOUR: The role of Der p 1
glycosylation in its uptake by DCs.
4.1 Introduction:
Allergens from the house dust mite Dermatophagoides
pteronyssinus were first found to be associated with
hypersensitivity reactions in 1967 (Spieksma FT, 1967). In
1969, Voorhorst identified the most significant house dust mite
allergen, Der p 1 (Voorhorst R, 1969), which later was found to
be a major cysteine protease allergen with a proteolytic activity
that digests critical cell surface molecules on dendritic cells, T
cells and B cells, thus provoking IgE production and allergy
(Shakib et al., 2008, Shakib et al., 1998, Voorhorst R, 1969).
It has been shown that up to 90% of individuals who are
sensitized to house dust mite allergens are actually responsive
to Der p 1 (Sharma et al., 2003, Richardson et al., 2005,
Thomas and Smith, 1998). Wan et al. found that Der p 1 was
able to break the tight junctions of the epithelial cells,
suggesting a role for Der p 1 in lung epithelium permeability
which contributes to sensitization and allergic responses (Wan et
al., 2000). Also, it has been clearly shown that Der p 1 affects
both innate and adaptive immune responses. For instance, it
induces mast cell and basophil degranulation, which via their
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cytokines (e.g. IL-4) influence IgE antibody production. There
has been a number of reports showing that Der p 1 can cleave
cell surface molecules that control IgE synthesis, like CD25 on T
cells, CD23 on B cells and CD40 on DCs (Ghaemmaghami et al.,
2002, Shakib et al., 1998). Der p 1 was also shown to cleave
DC-SIGN on DCs and DC-SIGNR expressed by endothelial cells
(Furmonaviciene et al., 2007). Researchers have shown that
proteolytically active Der p 1 suppresses IFN-Ǆ and enhances IL-
4 production by both CD4 and CD8 T cells, thus enhancing IgE
production by B cells and supporting an overall type 2 cytokine
response (Ghaemmaghami et al., 2001). It has also been
proposed that cleavage of CD40 on DCs by Der p 1 leads to the
production of less IL-12 by DCs. Furthermore, T cells co-cultured
with Der p 1 treated DCs produce more IL-4 and less IFN-Ǆ
which again directs the immune system towards a Th2 immune
response.
Atopic patients mount an exaggerated IgE immune response and
tend to polarise a Th2 immune response by producing IL-4, IL-5
and IL-13 (Commins and Platts-Mills, 2010, Kay, 2000). A
connection between high levels of thymic stromal lymphopoietin
(TSLP) secretion and induction of Th2 immune responses has
been established. TSLP is an IL-7-like cytokine expressed by
epithelial cells of mouse and human skin, gut, lungs and
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thymus. (He and Geha, 2010, Ziegler and Artis, 2010, Wang and
Liu, 2009, Soumelis et al., 2002). This cytokine was originally
identified in 1994 as a growth factor in culture supernatants of a
thymic stromal cell line to support the development of murine
immature B cells. Since then, TSLP has been shown to promote
B cells, T cells and Th 17 cell homeostasis; it also induces IL-4,
5 and 13 driven allergic inflammation and upregulates MHC I
and II co-stimulatory molecules CD40, CD80, CD83 and CD86
(Wang and Xing, 2008, Wang and Liu, 2009, Friend SL, 1994,
Ray et al., 1996, Tanaka et al., 2009, Miyata et al., 2009,
Soumelis et al., 2002). TSLP can activate DCs and increases
their expression of the ligand for T cell costimulatory molecule
OX40, thus enhancing Th2 immune responses (Wang and Liu,
2009, Ito et al., 2005, Rochman and Leonard, 2008).
There is a question as to why certain proteins can act as
allergens i.e. induce IgE production. The property in proteins
that may lead to allergenicity could be enzymatic activity,
though not all allergens are enzymatically active. Therefore
there could be other common features shared between allergens
that contribute to their allergenicity. One feature could be the
glycosylation pattern as research on the glycosylation features
of allergens have suggested that carbohydrates displayed by
allergens could be unique in structure or orientation and thus be
recognised by C-type lectin receptors (i.e. the mannose
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receptor (MR) on DCs) and this could favour Th2 polarization
and allergy (Shakib et al., 1998, Shreffler et al., 2006, Altmann,
2007, Taylor et al., 2005).
The mannose receptor is responsible for the recognition of
exposed mannose residues in pathogens and the internalization
of mannosylated antigens, thus enhancing their presentation to
lymphocytes. MR is composed of 3 extracellular regions: the
cysteine rich domain (CR domain) which recognises sulphated
sugars, a domain containing fibronectin type two repeats (FNII)
and the multiple C-type lectin-like carbohydrate recognition
domains (CTLDs) which recognize mannose, fucose and N-
acetylglucosamine (Taylor et al., 2005). There is an abundant
expression of MR on monocyte derived DCs where MR has been
shown to act primarily as an endocytic receptor. Work in our
group and that of others suggest that MR on DCs could play a
role in the recognition and uptake of Der p 1, and this has been
investigated in this chapter through labeling Der p 1 and
observing its uptake by DCs. The uptake of Der p 1 can be
inhibited by mannan, the natural ligand for MR, and after
downregulating the MR expression via gene silencing thus
demonstrating the importance of MR in the recognition of Der p
1 (Deslee et al., 2002, Royer et al., 2010).
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In recent years a number of different recombinant allergens
have been produced which have functional and immunological
similarities with their native counterparts. Recombinant allergens
were shown to be useful tools in studying allergen specific B and
T cell immune responses. It has become increasingly popular to
use yeast as a cellular host for the expression of recombinant
proteins. Pichia is easy to manipulate, faster and less expensive
to use than other eukaryotic expression systems, with the
advantage of having higher expression levels and the ability to
perform post-translational modification like glycosylation
(Cereghino and Cregg, 2000, Hamilton and Gerngross, 2007,
Jacquet et al., 2002, Yokoyama, 2003). In this chapter, the
recombinant preparation of Der p1 that was expressed in Pichia
pastoris was used as a hyper-glycosylated form of Der p 1
allergen to assess the extent to which glycosylation impacts on
Der p 1 uptake and recognition by the immune system.
In an attempt to investigate the role of glycosylation in allergen
recognition by the immune system, different glycoforms of Der p
1 were used to detect differences in uptake by DCs. A
recombinant preparation of Der p 1 produced in Pichia was used
as a hypermannosylated form of the allergen. The different Der
p 1 glycoforms were prepared using enzymatic and chemical
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deglycosylation of the allergen and an assessment of their
uptake by MR and DC-SIGN in immature DCs was carried out.
In this chapter, we also used the different glycoforms of Der p 1
produced, to assess any differences binding to murine MR cloned
sub-fragment (CTLD4-7-Fc), which is known to bind
mannosylated antigens and is shown to have the same
specificity as the natural MR sub-fragment (Linehan et al., 2001,
Martinez-Pomares et al., 2006).
We also measured changes in secretion of TSLP cytokine by
human epithelial cells when exposing them to different
glycoforms of Der p 1.
4.2 Materials and methods:
4.2.1 Generation of dendritic cells:
Dendritic cells were generated from peripheral blood-monocytes.
Briefly, Heparinized blood from house dust mite-sensitized
donors was obtained after prior consent and ethical committee
approval. The atopic status of donors was determined by skin
prick test (>3mm). Mononuclear cells (PBMC) were separated by
standard density gradient centrifugation on Histopaque
(HISTOPAQUE-1077, Sigma, Irvine, UK). PBMCs were collected
and washed. Purified PBMCs were incubated with mouse anti-
human CD14 monoclonal antibody conjugated to magnetic
beads (Miltenyi Biotec, Surrey, UK) at 4°C for 20 minutes. Cells
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were then washed and applied onto a column placed in the
magnetic field of a MACS separator (Miltenyi Biotec, Surrey,
UK). Negative cells were eliminated, and the column was
removed from the separator and eluted. CD14+ cells
(monocytes) were collected and washed with RPMI 1640 (Sigma,
Irvine, UK) and their purity was checked. Then they were
cultured (1 × 106 cells per well) in 48-well flat-bottomed culture
plates (Costar, High Wycombe, UK) in RPMI-1640 medium
supplemented with L-glutamine, antibiotics (Sigma, Irvine, UK)
and 10% fetal calf serum (FCS, Harlan Sera-Lab, Loughborough,
UK) containing 50 ng/ml of granulocyte-macrophage colony
stimulating factor (GM-CSF) and 250 U/ml of IL-4 [DC-medium]
(R&D Systems, Oxford, UK) at 37°C in 5% CO2 for 6 days.
On day 3 of culture, fresh DC-medium was added to the cell
cultures. On day 6, immature dendritic cells were harvested and
used in all the assays described.
4.2.2 Phenotype analysis:
Cells were washed with PBA (PBS, 1% v/v BSA and 0.1% w/v
sodium azide) and stained with the appropriate antibodies for 15
min, at 4 ºC in the dark. Cells were then washed twice with PBA
and fixed in 0.5% v/v formaldehyde in isotonic azide free
solution. Flow cytometry was performed using an EPICS Altra
Flow Cytometer (Beckman Coulter, Buckinghamshire, UK). At
least 5000 events were collected per sample and isotype
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matched antibodies were used to determine binding specificity.
The data were analysed using WinMDI version 2.8 (Joseph
Trotter, Scripps Institute, La Jolla, CA, USA). Dead cells were
excluded from analysis according to their forward and side
scatter characteristics.
The following monoclonal antibodies were used: anti-CD11c
[Phycoerythrin (PE), clone BU15], anti-CD40 [Phycoerythrin
(PE), clone MAB89], anti-CD80 [Fluorescein isothiocyanat, clone
MAB104], anti-CD83 [Fluorescein isothiocyanate, clone HB15a],
anti-CD86 [Phycoerythrin (PE), clone HA5.2B7], and anti-HLA-
DR [Phosphatidylcholine 5 (PC5), clone Immu-357] were all
purchased from Coulter Immunotech (Luton, UK).
4.2.3 Enzymatic deglycosylation:
To deglycosylate allergens, different enzymes were used.
PNGase A (Roche, Welwyn Garden City, U.K.) was used to
hydrolyse N-glycan chains from glycopeptides, specifically Į1,3-
bound core fucose residues. To hydrolyse 5 µg of Der p 1 50
units of PNGase A were used. Briefly, the reaction was diluted in
50 mM sodium acetate buffer with 5 mM CaCl2 supplemented
with 100 µg/ml BSA in 50 µl reaction volume at pH 5.5 and
incubated for 6 hrs at 37°C. The reaction was stopped by heat
inactivating the enzyme at 70°C for 10 mins. Then, 32 units of
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Į1-2,3 mannosidase, purchased from New England Biolabs
(Hitchin, Uk), was added and the reaction was incubated for
another 18 hrs at 37°C, then heat inactivated at 70°C. The other
enzyme used was PNGase F (New Englands Biolabs, Hitchin, Uk)
at 50 Units, the reaction was supplemented with 1% NP-40,
incubated for 6 hrs at 37°C and deactivated at 70°C. Commassie
staining Western blot analysis was done to confirm
deglycosylation.
4.2.4 SDS polyacrylamide gel electrophoresis (SDS-
PAGE):
All protein preparations were analysed by electrophoresis using
12% Novex Tris-Glycine precast gels from Invitrogen. Tris
Glycine running buffer (TGS) was prepared (30.3g Tris, 144g
Glycine and 10g SDS made up to 1 L with water) and protein
samples were run in XCell SureLock Mini-Cell from Invitrogen
under reducing conditions for 1hr 30mins at 125V. Samples
were diluted with 4X sample buffer (0.25M Tris-HCl pH 6.8, 8%
SDS, 30% Glycerol, 0.02% Bromophenol Blue and 0.3M DTT)
and heated to 95°C for 5 mins prior to loading. Protein
concentrations upon loading were up to 2 µg per well; 5µl of a
control pre-stained protein ladder (Fermentas) was added to
track sample migration in the first lane of the gel.
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4.2.5 Western blot analysis:
After gel electrophoresis, nitrocellulose membranes (Amersham,
UK) were cut, soaked in Tris Glycine (TG) blotting buffer (25mM
Tris pH8.5, 0.2M Glycine and 20% Methanol), gel and membrane
were assembled in an Invitrogen XCell II Blot Module apparatus
and soaked with 60 ml of TG blotting buffer. The gels were then
transferred for 1 hr at 30 V. When finished, the membranes were
blocked overnight with 5% BSA in TBS (0.05 M Tris-HCl, 0.15 M
NaCl at pH 7.5) at 4°C. In the glycan detection process, the DIG
Glycan Differentiation Kit from Roche was used. The membranes
were washed twice with TBS and once with buffer 1 (TBS; 1 mM
MgCl2, 1 mM MnCl2, 1 mM CaCl2 at pH 7.5). The required amount
of lectin solution was added (for GNA 10 µl each; for PNA 100 µl)
to 10 ml of buffer 1. These lectins that are Digoxigenin (DIG)
labelled were incubated separately for 1 hr with the membranes
and the membranes were then washed three times with TBS to
remove any unbound antibodies. The secondary antibody was
prepared (10 µl of anti-DIG conjugated to Alkaline phosphatise
(AP) diluted in 10 ml of TBS) and the membranes were incubated
with the antibody for one hour (Fig 4-1). The detection solution
was prepared by using 10 ml of Buffer 2 (0.1 M Tris-HCl, 0.05 M
MgCl2, 0.1 M NaCl at pH 9.5) diluted in 200 µl of NBT/BCIP
solution and the membranes were then incubated with the
detection solution for 20 mins in the dark (Colorimetric
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detection). The reaction was stopped by washing with ultra pure
H2O. Results were scanned using a BioRad GS800 Densitometer.
Positive and negative controls were provided with the DIG Glycan
detection kit and were used in the western blot experiments.
4.2.6 Periodate deglycosylation:
Der p 1 preparations were treated with sodium metaperiodate
(bought from Sigma-Aldrich inc.) at a molar ratio of 5:1
(Rasheedi et al., 2003, Okana et al., 1999a). The reaction
mixture was incubated for 30 and 60 mins at room temperature
in the dark. The oxidation process was stopped by adding 0.25
ml ethylene glycol per ml of sample. Samples were then dialyzed
at room temperature overnight against PBS. The preparations
were then labelled with Lightning-Link FITC Antibody Labeling
Kit from Novus Biologicals. Briefly, 1µl of LL-Modifier was added
for each 10 µl of allergen to be labeled and was then added to
Lightning-Link mix. The reaction was incubated in the dark for
3hrs followed by the addition of 1 µl of LL-quencher reagent for
every 10 µl of protein used.
4.2.7 Allergen uptake and inhibition assays:
The MD-DCs were washed and resuspended in uptake medium
consisting of RPMI (RPMI 1640, Sigma, Irvine, UK), phosphate
buffered saline (PBS) (Sigma, Irvine, UK) and 2% FCS (FCS,
Harlan Sera-Lab, Loughborough, UK). Natural Der p 1 (nDer p 1)
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preparations were labeled with Cy5 (GE heathcare, Bedford, UK)
in some experiments and FITC in others (Novus Bio, Cambridge,
Uk), while recombinant Der p 1 (rDer p 1) was labeled with
FITC. In the uptake assays cells were pre-incubated with
different natural and recombinant Der p 1 preparations (0.5 to
20 µg/ml) and their deglycosylated counterparts (1 µg/ml). In
the inhibition assays mannan (200 µg/ml), galactose-PAA (200
µg/ml) and rDer p 1 (0.5 to 20 µg/ml) were incubated with the
DC preparations for 20 mins at 37°C before the addition of Der p
1 and incubating for another 25 mins at 37°C. Cells were then
washed in uptake medium and the pellets were resuspended in
PBS containing 2% FCS.
The quantity of uptake of labeled natural and recombinant Der p
1 was then immediately determined with a BeckmanCoulter
Altra flow cytometer (Beckman-Coulter, High Wycombe, UK) and
expressed as mean fluorescence intensity (MFI). At least 10,000
cells per sample were analyzed.
4.2.8 Confocal imaging:
Day 6 immature DCs were collected and washed with warm
RPMI. rDerp1 (Indoor Biotechnology), labelled with FITC was
added at 1.0 µg/ml, N52Q rDer p 1 (an aglycosylated mutant
kindly provided from Dr T Takai, Allergy Research Center,
Juntendo University School of Medicine, Hongo, Tokyo, Japan)
labelled with Alexa 647 (Novus Bio, Cambridge, UK) was added
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at 1.0 µg/ml and nDer p 1 labelled with Cy5 (GE heathcare,
Bedford, UK) was added also at 1.0 µg/ml to cells. The cells
were then incubated at RT for 5, 10 15 and 30 mins, then fixed
with 4% formaldehyde and permeabilised with 0.1% triton X.
The following antibodies and labelling reagents were used for
cell staining, anti-MR (CD206) (PE; Clone 3.29B1.10, Coulter
Immunotech) anti-DC-SIGN (CD209) (PE; Clone AZND1, Coulter
Immunotech), anti-LAMP-2 PE; Clone GL2A7, Bioquote) ; Fluoro-
Trap Fluorescein Labeling Kit [FITC] was used according to
manufacturers protocol (Novusbio, UK). This reaction was
incubated for 30 mins at RT, then cells were washed again with
PBS and the supernatant was discarded. To label the nucleus,
DAPI stain (Thermo scientific) was diluted 1:100 with FBS and
1% BSA and added to all tubes. This reaction was incubated for
5 mins at RT, then cells were washed again with PBS and the
supernatant was discarded. Cells were fixed with 0.5%
formaldehyde, then the pellet was diluted with 200 µl PBS. Upon
imaging, the prepared samples were set up on poly-l-lysine
coated slides, covered with cover slips and imaged by LSM 510
meta Confocal Laser Scanning Microscopes (Carl Zeiss int.) at
40X and 60X. Negative controls of cells labelled with the stain
only (PE, Cy5, FITC) were used to set up the lasers upon
imaging. Co-localization and image analysis were done using the
LSM 510 image browser program.
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4.2.9 MR binding:
All washes and incubations were carried out in lectin buffer
consisting of 10 mM Tris-HCl, pH 7.5, 10mM Ca2+, 0.154M NaCl
and 0.05% (w/v) Tween 20. Different Der p 1 glycoforms at
concentration of 2µg/ml Der p 1 (Indoor Biotechnology UK),
periodate deglycosylated Der p 1 15 mins, periodate
deglycosylated Der p 1 30 mins and periodate deglycosylated
Der p 1 1 hr, rDer p 1 (Indoor Biotechnology UK), periodate
deglycosylated rDer p 1 15 mins, periodate deglycosylated rDer
p 1 30 mins, D Der p 1 (an aglycosylated mutant kindly provided
from Dr T Takai, Allergy Research Center, Juntendo University
School of Medicine, Hongo, Tokyo, Japan), as well as 2 µg/ml of
the corresponding carbohydrate ligand [Mannan (Sigma-Aldrich,
Irvine, UK) or Galactose (Gal-PAA) (Lectinity, Moscow, Russia)]
were used to coat the wells of Maxisorb ELISA plates (Nunc,
Roskilde, Denmark) by overnight incubation in PBS at 4°C. The
plates were washed three times and the MR subfragment
(CTLD4-7-Fc) (kindly provided by Dr Luisa Martinez-Pomares,
University of Nottingham, UK) was then added at 2 ǋg/ml and
incubated for 2 hours at room temperature. After three washes,
the binding was detected by incubation with anti-KXPDQ,J*Ǆ-
chain-specific alkaline phosphatase conjugate diluted 1:1000 in
lectin buffer (Sigma-Aldrich, Irvine, UK). Afterwards, plates were
washed three times with lectin buffer and two times with AP
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buffer consisting of 100mM Tris-HCl, 100 mM NaCl and 5mM
MgCl2 (pH 9.5), and subsequently developed with 100µl/well of
(1mg/ml) pNPP (Sigma-Aldrich, Irvine, UK) as a phosphatase
chromogenic substrate. Absorbance was measured at 405 nm on
a plate reader (Multiskan Ex, Labsystems, Helsinki, Finland). All
assays were carried out in triplicate.
4.2.10 Anti-Der p 1 5H8 ELISA:
Different natural unlabelled Der p 1 allergen preparations were
used Der p 1 (Indoor Biotechnology UK), periodate
deglycosylated Der p 1 15 mins, periodate deglycosylated Der p
1 30 mins and periodate deglycosylated Der p 1 1 hr, rDer p 1
(Indoor Biotechnology UK), periodate deglycosylated rDer p 1 15
mins, periodate deglycosylated rDer p 1 30 mins, D Der p 1 (an
aglycosylated mutant kindly provided from Dr T Takai, Allergy
Research Center, Juntendo University School of Medicine,
Hongo, Tokyo, Japan) at concentration of 2µg/ml, to coat the
wells of Maxisorb ELISA plates (Nunc, Roskilde, Denmark) by
overnight incubation in PBS at 4°C. The plates were washed
three times with TBS tween then 300µl of blocking buffer (TBS,
1% BSA) was added to each well and left for 1 hour. Plates were
washed and 5H8 anti-Der p 1 biotinylated antibody (Indoors
Biotechnology) was added and incubated at 2ǋg/ml for 2 hours
at room temperature. After three washes, the binding was
detected by incubation with Extra Avidin alkaline phosphatase
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conjugate diluted 1:1000 in TBS buffer (Sigma-Aldrich, Irvine,
UK). Afterwards, plates were washed two times with TBS tween
buffer and subsequently developed with 100µl/well of (1mg/ml)
pNPP (Sigma-Aldrich, Irvine, UK). Absorbance was measured at
405 nm on a plate reader (Multiskan Ex, Labsystems, Helsinki,
Finland). All assays were carried out in triplicate.
4.2.11 Cell culture:
Epithelial cell lines representing bronchial human lung (BEAS-
2B) were kindly provided by Professor Ian Hall (University of
Nottingham, UK). They were cultured in Dulbeccos Modified
Eagles Medium (Invitrogen), along with 10% low endotoxin
foetal bovine serum (Autogen Bioclear, UK), 2mM L-Glutamine
(Sigma) and 1% Penicillin/Streptomycin (Sigma). Cells were
cultured until 80% confluence, after which spent media was
aspirated and flasks were washed with 1x PBS. The cells were
then trypsinised using 0.25% trypsin-EDTA (Sigma) and
incubated for 5 minutes at 37°C, 5%CO2. According to the
number of cells to be re-passaged, cells were spun down for 5
minutes at 300 RPM. The resulting cell pellets were then re-
suspended thoroughly in the appropriate media and transferred
to T75 flasks (Corning) for culturing. The number of cells used
for each condition was 1 x 106 cells/ml. A cell count was
performed using a haemocytometer after staining with 0.1%
Trypan blue solution (Sigma) to exclude dead cells.
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4.2.12 Co-culturing BEAS-2B epithelial cells with
different Der p 1 glycoform preparations:
BEAS-2B cells were added to 24-well plates (Corning), together
with either 1µg/ml of Der p 1 (Indoors Biotechnology), periodate
deglycosylated Der p 1 (1µg/ml), rDer p 1 (Indoors
Biotechnology) (1µg/ml) or periodate deglycosylated rDer p 1
(1µg/ml). Then LPS (sigma) was added to all conditions at
50ng/ml. For some experiments human normal lung bronchial
fibroblasts provided by City Hospital (Nottingham, UK) were co-
cultured with epithelial cells for 48 hrs until confluent. Plates
were then incubated at 37qC, 5% CO2 for 24 hours. At the end of
incubation, supernatants were carefully collected from wells and
transferred to sterile 1.5ml eppendorf tubes (Axygen), then
frozen at -20ºC.
4.2.13 TSLP ELISA:
Levels of human TSLP (hTSLP) in epithelial cell culture
supernatants were measured with a Human TSLP ELISA
development kit, which was purchased from Biolegend and can
detect human TSLP concentration to a minimum of 4pg/ml.
Briefly, 96-well plates (Nunclon) were coated with TSLP capture
antibody diluted 1:200 from 200X stock solution and incubated
overnight. All incubations were carried out at room temperature,
and plates were aspirated and washed 4 times with wash buffer
(0.05%Tween-20 in 1xPBS, Sigma) between steps. Following
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overnight incubation, 300µl of blocking buffer provided with the
kit was added to each well and left for 1 hour. Then, 100µl of
samples and standards (prepared by serial dilutions to obtain a
range of 7.8 - 500pg/ml) were added to appropriate wells and
incubated for 2 hours. Following this, the detection antibody was
added and incubated for another 1 hour. The plate was washed
4 times then 100µl of Avidin-HRP conjugate that is provided by
the kit was added to each well and left for 30 minutes. Finally,
100µl per well of substrate solution F (Biolegend) was added and
incubated in the dark for 15 mins, then the reaction was
stopped by adding 100 µl of stop solution to each well. The plate
was read by an ELISA plate reader (Labsystems, Multiskan EX)
at a wavelength of 450nm.
4.2.14 CD4+ T cell separation:
Using the Pan T cell separation kit (Miltenyi Biotec, Surrey, UK),
the negative fraction collected after separating CD14+ cells from
PBMC was washed with RPMI 1640 (Sigma, Irvine, UK), then
human T cells were isolated by depletion of non-T cells (negative
selection). Non-T cells are indirectly labeled with a cocktail of
biotin conjugated monoclonal antibodies (CD14, CD16, CD19,
CD36, CD56, CD123, and CD235a) as primary labeling reagent,
and anti-biotin monoclonal antibodies conjugated to MicroBeads,
as secondary labeling reagent. The magnetically labeled non-T
cells are depleted by retaining them on a MACS® Column in the
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magnetic field of a MACS Separator, while the unlabeled T cells
pass through the column. The purity of the enriched T cell
fraction was evaluated by flow cytometry against CD3 FITC
antibody. Cells were then washed by MACS buffer, centrifuged
and resuspended in 500µl of buffer. Then using the CD4 naive T
cell isolation kit (CD45RO microbeads from Miltenyi Biotec,
Surrey, UK), human DC4+ T cells were isolated by depletion of
non-CD4+ T cells (negative selection). Again, non-CD4+ T cells
are indirectly labeled with CD45RO biotin conjugated monoclonal
antibody, as primary labeling reagent, and anti-biotin
monoclonal antibodies conjugated to MicroBeads, as secondary
labeling reagent. The magnetically labeled non-CD4+ T cells are
depleted by retaining them on a MACS® Column in the magnetic
field of a MACS Separator, while the unlabeled CD4+ T cells pass
through the column. The purity of the enriched CD4+ T cell
fraction was evaluated by flow cytometry.
4.2.15 DC-CD4+ T cell Co-Culture:
The immature DCs generated were collected at day 6 and
activated by the enriched TSLP supernatant produced by
culturing BEAS-2B epithelial cells with different Der p 1
glycoform preparations, in addition to recombinant TSLP
standard (Biolegend, UK). For each condition, 2 x 105 DCs were
used and 500µl of TSLP supernatant was added. All the
conditions were incubated for 6 hours at 37°C, 5%CO2, then the
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supernatant was removed and the cells were washed thoroughly
with warm RPMI 1640 (Sigma, Irvine, UK).
The activated DCs were then co-cultured with naive CD4+ T cells
for 7 days at a ratio of 1:1 in a round bottomed 96-well culture
plates. In some experiments immature DCs were directly
stimulated with different glycoforms of Der p 1 and recombinant
Der p 1 for 24 hrs then co-cultured with CD4+ naive T cells for
10 days. The cytokine secretion for IL-4 and IFN-ɶ was then
measured. Medium used for the co-culture was RPMI 1640
supplemented with penicillin/streptomycin and 5% human AB
serum (Sigma-Aldrich). On day 3, the culture was fed with IL-2
(20 IU/ml; R&D Systems). At day 7, T cells were re-stimulated
for 8 h with PMA (15 ng/ml) and ionomycin (1mg/ml) (both from
Sigma-Aldrich). The supernatants were collected and stored at -
20°C.
4.2.16 Cytokine measurement:
Cytokine secretion was analysed with the FlowCytomix kit
(Bender MedSystems Vienna, Austria) according to
manufacturers instructions.
4.2.17 Statistical analysis
Statistical analysis of the data was carried out using Students t-
test because of the small number of replicates being used, P-
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values < 0.05 were considered significant. Data were expressed
as the MFI ± SDM, number of independent experiments 3.
4.3 Results:
4.3.1 Comparative analysis of natural and
recombinant Der p 1 uptake by immature DCs:
Both natural and recombinant Der p 1 preparations are
glycosylated (see chapter 2). In this project we proved that the
recombinant preparation is hyperglycosylated and has much
more mannan than the natural Der p 1. To investigate the effect
of hyperglycosylation on the uptake of Der p 1 allergen by DCs
we incubated both preparations under the same conditions in
vitro with immature DCs at 37°C. Both preparations were
labelled by FITC and thus the uptake could be measured
comparatively by flow cytometry as MFI readings. The control
conditions for these experiments were DCs incubated with
allergens at 4°C and DCs only. Levels of allergen uptake for
each condition is presented as MFI (Fig 4-1) and is also
visualised using confocal imaging (Fig 4-2). The results suggest
that the average mean of uptake for the recombinant Der p 1
(hyperglycosylated allergen) is significantly higher than that of
the natural one. To investigate the effect of deglycosylation of
allergens on their uptake N52Q was used, which is a
deglycosylated preparation of recombinant Der p 1, it showed a
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lower uptake compared to the recombinant hyperglycosylated
preparation (Fig 4-3). In other experiments the uptake of
natural Der p 1 was blocked by rDer p 1 in a dose dependent
manner (Fig 4-4). This inhibition of nDer p 1 uptake reached
62.5% upon adding 20ug/ml rDer p 1 preparation to the DCs.
This was also confirmed by confocal imaging (Fig 4-5).
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Fig 4-1: MFI ± SDM readings which represent the difference in
uptake between natural and recombinant Der p 1 (1µg/ml) by
immature DCs. There was a significant difference between native
and recombinant uptake at the same concentration. The results
suggest that the average mean of uptake for the recombinant
preparation is higher than that for the natural one, the results
also show that the uptake of Der p 1 by immature DCs at 4°C is
lower than the uptake at 37°C for both preparations. Both
natural and recombinant Der p 1 were labelled with FITC and
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incubated at 4°C and 37°C for 20 mins with DCs . *P
value<0.05, number of independent experiments=3.
Fig 4-2: Confocal images of the difference between recombinant
and natural Der p 1 (0.5 µg/ml) uptake by immature DCs. The
results suggest that the uptake of the recombinant preparation
(A) is higher than that for the native one (B) in the same DC. A.
Green:rDer p 1 labelled with FITC, red:MR labelled with PE,
blue:nucleus labelled with DAPI. B. Green:nDer p 1 Labelled with
Cy5, red:MR labelled with PE, blue:nucleus labelled with DAPI,
number of independent experiments=3.
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Fig 4-3: Confocal images of the difference between recombinant
Der p 1 and recombinant N52Q Der p 1 (0.5 µg/ml) uptake by
immature DCs. The results suggest that the uptake of the
recombinant hypermannosylated Der p 1 preparation (A) is
higher than that for the recombinant hypomannosylated Der p 1
(N52Q) (B) in DCs. A. Green:rDer p 1 labelled with FITC, red:MR
labelled with PE, blue:nucleus labelled with DAPI.B. Green:N52Q
Der p 1 Labelled with Alexa 647, red:MR labelled with PE,
blue:nucleus labelled with DAPI, number of independent
experiments=3.
When examining the uptake of recombinant and natural Der p 1
preparations at different timepoints by confocal imaging, there
seems to be a different pattern in uptake i.e. rDer p 1 is diffused
whereas native Der p 1 is localised on cell memberane (Fig 4-2
& 4-3). The recombinant preparation seems to be internalized
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immediatly by DCs after 5 mins incubation while the natural
preparation only started to be taken up at 10 mins (Figs 4-6 &
4-7). The uptake of both preparations was studied at 20 and 30
mins (Fig 4-8 & 4-9). These images also show the co-localisation
of both preparations by MR. When analysing the co-localization
of natural and recombinant preperations with MR by the LSM
510 image browser, the co-localization coeffecient was found to
be higher for rDer p 1 (Figs 4-10 & 4-11). The analysis also
showed that these preparations co-localise inside the cell
suggesting a similar intracellular fate (Fig 4-12). Recombinant
and natural Der p 1 also co-localised with DC-SIGN (Fig 4-13)
and with the Lysosomal-associated membrane protein 2 (LAMP-
2), which shuttles between lysosomes, endosomes and the
plasma membrane (Fig 4-14).
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Fig 4-4: natural Der p 1 uptake by immature DCs represented as
MFI ± SDM readings when adding different concentrations of
rDer p 1 to the DCs (up to 20µg/ml) and mannan (200µg/ml).
There was a significant decrease in uptake of natural Der p 1
when comparing the preparations before and after adding rDer p
1; after adding 5 µg/ml of rDer p 1 to the DCs then adding
1µg/ml concentration of natural Der p 1, the uptake of natural
Der p 1 was decreased by 42% on average compared to the
natural uptake alone at 1µg/ml, this inhibition of uptake is
dependent on rDer p 1 addition concentration as the higher the
concentration of rDer p 1 the more the Der p 1 uptake is
inhibited. The inhibition of natural Der p 1 uptake reached
62.5% when adding 20µg/ml of rDer p 1 .Natural Der p 1 was
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labelled with Cy5, rDer p 1 was not labelled.*** P value<0.001.
number of independent experiments=3
A. B. C.
rDer p 1 nDer p 1 Control of uptake of nDer p 1
Fig 4-5: In A & B the uptake of nDer p 1 at 1µg/ml by the same
immature DCs when adding 10 µg/ml of rDer p 1. C. Is the
control of uptake of n Der p 1 when no rDer p 1 is added. The
images suggest that the uptake of nDer p 1 (1µg/ml) (B) is
inhibited after adding (10µg/ml) of rDer p 1 (A) in the same
DCs. A. Green: rDer p 1 stained with FITC, B. purple: nDer p 1
stained with Cy5, C. Purple: Control slide of nDer p 1 stained
with Cy5 (1µg/ml) uptake when no rDer p1 added, number of
independent experiments=3.
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A.
rDer p1 MR Merged image
B.
nDer p 1 MR Merged image
Fig 4-6: The uptake of recombinant and natural preparations of
Der p 1 (1 µg/ml) by immature DCs at 5 mins. The image shows
that at 5 mins the recombinant preparation is inside the DCs
while the natural is not. A. Green: rDer p1 stained with FITC,
red:MR stained with PE, blue: nucleus stained with DAPI, B.
Green: nDer p 1 stained with Cy5, red: MR stained with PE,
blue: nucleus stained with DAPI, number of independent
experiments=3.
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A.
rDer p1 MR Merged image
B.
nDer p1 MR Merged image
Fig 4-7: The uptake of recombinant and natural preparations of
Der p 1 (1 µg/ml) by immature DCs at 10 mins. The image
shows that at 10 mins both preparations are inside the DCs A.
Green: rDer p1 stained with FITC, red: MR stained with PE, B.
Green: nDer p 1 stained with Cy5, red: MR stained with PE,
number of independent experiments=3.
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A.
rDer p1 MR Merged image
B.
nDer p1 MR Merged image
Fig 4-8: The uptake of recombinant and natural preparations of
Der p 1 (1 µg/ml) by immature DC at 20 mins. A. Green: rDer
p1 stained with FITC, red: MR stained with PE, blue: nucleus
stained with DAPI. B. Green: nDer p 1 stained with Cy5, red: MR
stained with PE, blue: nucleus stained with DAPI, number of
independent experiments=3.
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A.
rDer p1 MR Merged image
B.
nDer p1 MR Merged image
Fig 4-9: The uptake of recombinant and natural preparations of
Der p 1 (1 µg/ml) by immature DCs at 30 mins. A. Green: rDer
p1 stained with FITC, red: MR stained with PE, blue: nucleus
stained with DAPI. B. Green: nDer p 1 stained with Cy5, red: MR
stained with PE, blue: nucleus stained with DAPI, number of
independent experiments=3.
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Fig 4-10: rDer p 1 (FITC labelled) co-localization analysis with
MR (PE labelled) using the LSM image browser 510, Co-
localization coeffcient: 0.911, Overlap coefficient:1.0. The
results indicate that there is co-localisation between the MR and
rDer p 1 inside the DC.
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Fig 4-11: nDer p 1 (Cy 5 labelled) co-localisation anlysis with MR
(PE labelled) using the LSM image browser 510. Co-localization
coeffcient: 0.84, Overlap coefficient:0.9. The results indicate that
there is co-localisation between the MR and nDer p 1 inside the
DC.
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Fig 4-12: nDer p 1 (Cy 5 labelled) co-localisation anlaysis with
rDer p 1 (FITC labelled) using the LSM image browser 510. Co-
localization coefficient:0.73, Overlap coefficient:1.0. The results
indicate that there is co-localisation between the nDer p 1 and
rDer p 1inside the DC.
rDerp1 DC-SIGN Merged image
nDerp1 DC-SIGN Merged image
Fig 4-13: The co-localisation of native and recombinant Der p 1
(0.5 µg/ml) in immature DCs with DC-SIGN detected at 10 mins.
rDer p 1 co-localization coeffcient with DC-SIGN:0.83, nDer p 1
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Co-localization coeffcient with DC-SIGN:0.75. A. Green: rDer p1
stained with FITC, red: DC-SIGN stained with PE, B. Green:
nDer p 1 stained with Cy5, red: DC-SIGN stained with PE,
number of independent experiments=3.
rDerp1 LAMP-2 Merged image
nDerp1 LAMP-2 Merged image
Fig 4-14: The co-localisation of native and recombinant Derp1
(0.5 µg/ml) with LAMP-2 detected at 10 mins. rDer p 1 Co-
localization coeffcient with LAMP-2:0.88, nDer p 1 Co-
localization coeffcient with LAMP-2:0.71. A. Green: rDer p1
stained with FITC, red: MR stained with PE, blue: nucleus
stained with DAPI. B. Green: nDer p 1 stained with Cy5, red: MR
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stained with PE, blue: nucleus stained with DAPI. number of
independent experiments=3.
4.3.2 Enzymatic deglycosylation of natural and
recombinant Der p 1:
In order to get different glycoforms of the same Der p 1
preparation and investigate the difference between their
recognition by the immune system, enzymatic deglycosylation
was used to try to specifically demannosylate the different
allergen preparations. Three enzymes were used to achieve
minimal glycosylation levels of natural and recombinant Der p 1
preparations. We used PNGase A that digests N-glycan chains, in
particular the Į1,3-bound core fucose residue. We also used 1,3
and 1,2 mannosidase and PNGase F that cleave between the
innermost GlcNAc and asparagine residues of high mannose,
hybrid, and complex oligosaccharides from N-linked
glycoproteins. Examining allergen preparations after
deglycosylation showed that the molecular weight of the
recombinant Der p 1 preparation dropped from 37kD to around
25kD and it no longer migrated as a diffuse band (Fig 4-15, well
9). This suggests that a lot of sugars were broken down as they
appear as a band at 10kD in well 9. The natural Der p 1
preparation did not show a drop in molecular weight and still
migrated as a diffuse band, which suggests that either the
demmanosylation process did not work or that there was only a
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small amount of mannan present on the protein and most of the
glycosylation in Der p 1 is due to other sugars like galactose
(see chapter 2).
Fig 4-15: Deglycosylation of natural and recombinant Der p 1
with PnGase A (PnA), 1,2 1,3 Mannosidase (Mann) and PNGase F
(PnF). Well 1:marker, well 2:nDer p 1, well 3: nDer p 1 digest
with PnA, well 4:nDer p 1 digest with PnA and Mann, well 5:nDer
p1 digest with PnA, Mann and PnF, well 6: r Der p 1, well 7: rDer
p 1 digest with PnA, well 8:rDer p 1 digest with PnA and
mannosidase, well 9: rDer p 1 after deglycosylation with the
PnA, Mann and PnF enzymes. This is a blot against anti-
galactose PNA , number of independent experiments=2.
The demannosylated recombinant Der p 1 preparation was
labelled with FITC and its uptake by DCs was compared to the
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hypermannosylated allergen using flowcytometry (Figs 4-16 & 4-
17). The results indicate a significant decrease in the uptake of
demannosylated Der p 1 by immature DCs compared with the
untreated allergen. Pre incubation of DCs with mannan
(200ug/ml) prior to addition of untreated recombinant Der p 1
preparation resulted in significant inhibition in its uptake by
88%. This result was also confirmed by confocal imaging (Fig 4-
18). This experiment confirmed the importance of mannan in the
uptake of rDer p 1 allergen.
14.135
29.1
68.1
114
14.99 13.84
0
20
40
60
80
100
120
140
160
Cells only 4°C uptake
rDer p1
(0.5µg/ml)
rDer p 1 (0.5
µg/ml)
rDer p1 (1.0
µg/ml)
Deg rDer p 1
(1.0 µg/ml)
Mann+rDer p
1(200 µg/ml)
M
FI
***
Fig 4-16: The MFI ± SDM readings for the uptake of different
concentrations of rDer p 1 by immature DCs compared to
enzymatically deglycosylated rDer p 1 using PNGase A,
mannosidase and PNGase F, the results indicate a significant
decrease in the uptake of demannosylated rDer p 1 by
immature DCs compared with the undigested allergen. ***P
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value<0.001, rDer p 1 was labelled with FITC. number of
independent experiments=3
Fig 4-17: DC populations expressed as histogram by the WIN
MDI 2.9 program after the uptake of different rDer p1
preparations. Red: cells only, Black: rDer p 1 1ug/ml, green:
demannosylated rDer p 1 1µg/ml, blue: mannan 200
µg/ml+rDer p 1 1µg/ml.
Chapter 4 Der p 1 glycoforms uptake by DCs
140
A.
Mannan+ rDer p 1 MR Merged image
Control of the uptake of rDer p 1 (Green) by DCs without the addition of mannan
B.
Mannan+ nDer p 1 MR Merged image
Control of the uptake of nDer p 1 (Green) by DCs without the addition
of mannan
Fig 4-18: Confocal image showing the inhibition of uptake of
rDer p 1 and nDer p 1 when adding mannan to the cells at 200
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µg/ml. The recombinant and natural Der p 1 concentration used
is 1 µg/ml. The results shows that there is minimal uptake for
both preparations upon adding mannan to the immature DCs
compared to previous results with no mannan addition. A.
Green: rDer p1 stained with FITC, red: MR stained with PE, blue:
nucleus stained with DAPI. B. Green: nDer p 1 stained with Cy5,
red: MR stained with PE, blue: nucleus stained with DAPI,
number of independent experiments=3.
4.3.3 Sodium periodate deglycosylation of native and
recombinant Der p 1:
Another method was used to try and deglycosylate both native
and recombinant Der p 1 preparations by using sodium
metaperiodate oxidation. Periodate has been used in the
literature to deglycosylate protein preparations (Perlin, 2006,
Lipniunas et al., 1992, Philip E. Thorpe, 1988, Okano et al.,
1999). Natural and recombinant Der p 1 were incubated with
periodate in the dark at room temperature for 30 and 60 mins.
A western blot against GNA (anti 1-2,3,6 mannose was
performed on the samples before and after periodate treatment
(Fig 4-19) to confirm that demannosylation had worked.
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Fig 4-19: Western blot against GNA (anti-mannose) of natural
and recombinant Der p 1 before and after periodate treatment
for 60 mins. The blot shows minimal reaction with GNA for both
preparations after periodate treatment, indicating that periodate
removed most of mannan. The concentration of the protein
loaded in each well was 2.0 µg/ml, number of independent
experiments=2.
Preparations were then labelled with FITC and the uptake by
DCs was measured against untreated preparations (Figs 4-20 &
4-21).
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Fig 4-20: Uptake of different Der p 1 preparations by immature
DCs. Red:cells only, Black: 0.5 µg nDer p 1 , green :30 mins
periodate of 0.5 µg nDer p 1, blue: 1 hr treatment of nDer p 1
(1 µg/ml).
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Fig 4-21: The MFI ± SDM readings for the uptake of different
concentrations of nDer p 1 and rDer p 1 by immature DCs compared
to the periodate treated preparations. Both n Der p 1 and rDer p 1
were treated with periodate for 30 mins and 1 hr, then their uptake
was measured. The results shows a significant decrease in uptake of
periodate treated preparations compared with the untreated
ones.*** P value<0.001, all Der p 1 preparations were labelled with
FITC. number of independent experiments=3
The results indicate a significant decrease in the uptake of both
Der p 1 preparations after periodate treatment. The recombinant
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periodate treated preparation (1µg/ml) showed a 53% decrease
in uptake after 30 mins of treatment compared to the untreated
preparation of the same concentration; at 60 mins of periodate
oxidation, the uptake decreased to 81.6%. The natural periodate
treated sample showed a decrease of 58.7% after 30 mins of
periodate treatment and 90% decrease in uptake after 60 mins
of oxidation (Figs 4-20 & 4-21). Confocal imaging after 1 hr of
periodate reaction showed minimal uptake by DCs for both Der p
1 preparations compared to untreated proteins (Fig 4-24 A & B).
To highlight the importance of mannosylation in the uptake of
proteins, a non-mannosylated cysteine protease, namely
Staphopain B from Staphylococcus aureus (see chapter 2), was
examined for its uptake by DCs compared to Der p 1 (natural
and recombinant) and to the periodate treated preparations
(Fig 4-22 & 4-23). The percentage uptake of natural Der p 1
compared to Staphopain B was higher by 64%. Confocal imaging
for the uptake of Staphopain B showed a lower quantity of it
inside DCs compared to the natural and recombinant
preparations of Der p 1 (Fig 4-24 C).
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Cells only nDerp1 0.25µg/ml nDerp1 0.5µg/ml nDer p 1 1.0µg/ml
nDerp1(1µg/ml)+periodate 1hr rDerp1 1µg/ml rDerp1 5µg/ml rDerp1 10µg/ml
rDerp1(1µg/ml)+ +period 1hr Staphopain B
Fig 4-22: Representative dot plots of immature DC populations
expressed as a histogram and as cell population by the WIN MDI
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2.9 program after the uptake of different rDer p1 preparations
and Staphopain B. Red: cells only, black: rDer p 1 0.5 µg/ml,
green: r Der p 1 1.0 µg/ml, blue: periodate treated rDer p 1 1.0
µg/ml for 1 hr, purple: Staphopain B 1.0 µg/ml. All Der p 1
preparations were labelled with FITC. Staphopain B was labelled
with FITC.
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Fig 4-23: The MFI± SDM readings for the uptake of different
concentrations of nDer p 1 and rDer p 1 by immature DCs
compared to the periodate treated preparations and Staphopain
B uptake. The results shows a decrease in uptake upon treating
nDer p 1 and rDer p 1 with periodate.*** P value<0.001. All Der
p 1 preparations were labelled with FITC. Staphopain B is also
Labelled with FITC. number of independent experiments=3
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To examine if mannan is the only inhibitor of Der p 1 uptake of
allergens we examined the effect of galactose on uptake, DCs
were incubated with a galactose polymer (200 µg/ml) and
mannan (200 µg/ml) for 20 mins at 37°C and the uptake of Der
p 1 was measured (Fig 4-25)4. The results indicate that
galactose has no significant effect on the uptake of Der p 1 by
DCs. At lower concentrations of galactose and mannan (50
µg/ml), mannan inhibited the uptake of Der p 1 while galactose
did not (Fig 4-26)
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A.
Periodate treated rDer p 1 MR Merged image
Control of rDer p 1 uptake(Green) with no periodate treatment
B.
Periodate treated nDer p 1 MR Merged image
Control of nDer p 1 uptake (Green) with no periodate treatment
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C.
Staphopain B MR Merged image
Fig 4-24: Confocal images showing the uptake of rDer p 1 and
nDer p 1 when treated with sodium periodate for 1hr. The
recombinant and natural Der p 1 concentration used is 1 µg/ml.
Staphopain B was also used at a concentration of 1 µg/ml. The
images show minimal uptake of periodate treated samples.
Image C also shows reduced uptake of Staphopain B compared
to the uptake of nDer p 1 allergen. A. Green: rDer p1 stained
with FITC, red: MR stained with PE, blue: nucleus stained with
DAPI. B. Green: nDer p 1 stained with Cy5, red: MR stained with
PE, blue: nucleus stained with DAPI. C. Green: Staphopain B
stained with FITC, red: MR stained with PE, blue: nucleus
stained with DAPI, number of independent experiments=2.
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Fig 4-25: The MFI ± SDM readings for the uptake of different
concentrations of nDer p 1 and rDer p 1 (1 µg/ml) by immature
DCs compared to their uptake when adding galactose at 200
µg/ml. Adding galactose did not affect the uptake of nDer p 1
and rDer p 1. P value> 0.05 is considered non-significant.
number of independent experiments=3.
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Fig 4-26: The MFI ± SDM readings for the uptake of different
concentrations of nDer p 1 by immature DCs compared to
uptake when adding galactose and mannan at 50 µg/ml. adding
mannan at a concentration of 50µg/ml reduced the uptake of
nDer p1 while adding galactose at the same concentration of
50µg/ml did not affect the uptake of nDer p 1, number of
independent experiments=1.
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nDer p 1 MR merged image
Fig 4-27: Confocal images showing the uptake of nDer p 1
(1µg/ml) by immature DCs when adding galactose at 200 µg/ml.
The image shows that there is an uptake for nDer p1 after
saturating the DCs with galactose, number of independent
experiments=3. (Compare to mannan inhibition of uptake in Fig
4-18B)
4.3.4 MR binding of the different glycoforms of Der p 1:
The different glycoform preparations of Der p 1 were shown in
chapter 2 & 4 to contain different carbohydrate contents. It was,
therefore, of interest to know if the binding to MR subfragment
CTLD 4-7, the C-type lectin carbohydrate recognition domain,
will differ according to the carbohydrate content of the
glycoforms. Mannan and galactose were used as positive and
negative controls, respectively. Results in Fig 4-28 show a
significant decrease in binding to MR (>55%) when Der p 1
allergen is deglycosylated with periodate for 60 mins. The same
is noticed when treating hypermannosylated rDer p 1 with
periodate for 60 mins as the decrease in binding after
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deglycosylation reached 42.5%. It is clear that the binding of
the recombinant preparation of Der p 1 to MR is much stronger
than that of natural Der p 1 which is expected as rDer p 1 has
more mannan than natural Der p 1 (shown in chapter 2).
Another recombinant glycoform used here is D Der p 1, which is
an Aglycosylated recombinant preparation that was produced
through a mutation in rDer p 1 glycosylation site. This
preparation binds MR less than the recombinant Der p 1 by
27%. Fig 4-29 shows that the periodate-treated glycoforms still
bind 5H8 anti-Der p 1 antibody, indicating that periodate
treatment did not change the conformation of the protein, but
just altered the sugar content.
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Fig 4-28: Binding of MR C-type lectin-like carbohydrate
recognition domains 4-7 with different glycoforms of Der p 1:
Der p 1, rDer p 1 and D Der p 1 (recombinant deglycosylated
Der p 1 with mutation N52Q) (concentrations at 2µg/ml). ***P
value < 0.001, number of independent experiments=3.
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Fig 4-29: Binding of anti-Der p1 5H8 antibody to different
glycoforms of Der p 1 (2µg/ml), number of independent
experiments=2.
4.3.5 Differences in TSLP secretion induced by the
different glycoforms of Der p 1:
The next step in showing that the glycan content of allergens
could alter the outcome of Th1/Th2 immune responses is by
measuring Th2 cytokine secretions after exposure to allergens.
An initial example of this is TSLP secretions that are secreted by
epithelial cells in humans and mice and are thought to induce
Th2 immune responses. We incubated the different glycoforms
of Der p 1 with human epithelial cells for 24 hrs, then TSLP was
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measured by a human TSLP development kit. Results in Fig 4-30
& 4-31 show a significant increase in TSLP secretion by human
epithelial cells when challenged by Der p 1, and this increase in
TSLP becomes less pronounced when periodate deglycosylated
Der p 1 was used. However, we were unable to reproduce this
pattern with the recombinant preparation of Der p 1. The
increase in the secretion of TSLP by human epithelial cells upon
stimulation with Der p 1 may therefore lead to a Th2 biased
immune response.
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Fig 4-30: Differences in TSLP secretion in human BEAS-2B
epithelial cells after 24 hrs stimulation with different glycoforms
of Der p 1. Concentration of Der p 1 used was 1 µg/ml. ***P
value < 0.001, number of independent experiments=3.
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Fig 4-31: Differences in TSLP secretion in human BEAS-2B
epithelial cells when co-cultured for 48 hrs with human Lung
bronchial fibroblasts cells and then stimulated with different
glycoforms of Der p 1 for 24 hrs. Concentration of Der p 1 used
was 1 µg/ml. ***P value < 0.001, number of independent
experiments=3.
4.3.6 Differences in T cell cytokine secretion induced by
different glycoforms of Der p 1:
To investigate the impact of Der p 1-induced TSLP secretion in
human epithelial cell media on T cell cytokine profile, TSLP-
conditioned human DCs were co-cultured with autologos T cells
and IL-4, 5, 13 and IFN-ǄF\WRNLQHVHFUHWLRQVZHUHPHDVXUHG
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Results shown in Fig 4-32 is for atopic blood and the data for
donors 2 and 4 indicate a high IL-5 and IL-13 on average upon
induction with high TSLP enriched media (produced via natural
Der p 1 stimulation of epithelia) compared to low TSLP induction
produced though stimulating the epithelial cells with
deglycosylated Der p 1 preparations. Donors 1, 2 and 3 however
showed a very high IFN-Ǆ when low TSLP induction was used
upon stimulation with periodate deglycosylated Der p 1. This
may indicate a shift towards a Th1 immune response when
deglycosylating Der p 1. Upon introducing an antibody against
TSLP in donors 4-6 to the epithelial media that is stimulated with
native Der p 1, cytokine secretion decreases on average, which
may suggest that TSLP cytokine is responsible for increasing IL-
5 and IL-13 cytokine secretion that eventually lead to Th2 bias
immune response.
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Fig 4-32 : T cell cytokine secretion upon stimulating DCs with
different TSLP containing media and co-culturing them with T
cells in vitro (atopic human blood). In donors 1, 2 and 3 there is
an increase in IFN-ɶ secretion upon stimulation with
deglycosylated preparations of Der p 1 compared to lower IFN-ɶ
secretion when native Der p 1 is used. There is an overall
decrease in IL-5 and 13 secretions when using deglycosylated
Der p 1 preparations in donors 2 and 4. Donors 5 and 6 had no
change in cytokine secretions upon glycoforms stimulation,
number of independrnt experiments=6.
4.4 Discussion:
This work is an attempt to gain a better understanding of the
role of glycosylation in Der p 1 recognition by the innate immune
system. The recombinant Der p 1 preparation used in this study
was produced in Pichia pastoris and as such it is
hypermannosylated (Cereghino et al., 2002, Cregg, 2007). It is
therefore interesting that this highly mannoasylated preparation
was taken up more readily by DCs than natural Der p 1, and this
underlines the importance of sugars in allergen recognition by
MR and presumably by DC-SIGN (Royer et al., 2010, Taylor et
al., 2005, Geijtenbeek et al., 2000, Hsu SC, 2010). This was
further confirmed by the demonstration that the
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hypermannosylated recombinant Der p 1 preparation was able
to inhibit, the uptake of natural Der p 1 by DCs.
Mannan itself inhibited the uptake of both recombinant and
natural Der p 1 by up to 88% and 83% respectively, which is
expected given that mannan is the natural ligand for MR.
Moreover, the mannose receptor has been shown to play a key
role in the uptake of diverse allergens by human DCs and in the
bias towards the Th2 phenotype (Royer et al., 2010, Taylor et
al., 2005, Deslee et al., 2002).
The above data were further corroborated by demannosylating
rDer p 1 via a combination of enzymes and chemical
deglycoslatiom resulting in a preparation exhibiting minimal
uptake by DCs. This was best exemplified by sodium
metaperiodate treatment of rDer p 1. Sodium metaperiodate
treatment does not affect the protein under mild conditions, and
in one study it was shown that at 10 mM could lead to structural
alterations in carbohydrates without any significant effect on
proteins in Schistosoma mansoni Egg Antigens (Okano et al.,
1999). Periodate was also used to destroy carbohydrates on Cry
j 1, the major allergen of Japanese cedar pollen, and it was
shown that after periodate oxidation Cry j 1-specific CD4+ T cell
proliferation decreased significantly and there was also
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significantly less IL-4 and IL-5 secretion in comparison with the
control antigen (Mitsuhiro et al., 2001). Consequently, those
authors suggested a role for carbohydrates on Cry j 1 in
promoting Th2 immune responses in vitro.
The confocal images provided an insight into the uptake of
different Der p 1 preparations by DCs. It became clear that the
internalization of Der p 1 is initiated by MR on immature DCs.
Confocal imaging also showed that recombinant Der p 1 uptake
is immediate, starting at 5 mins of incubation and that a higher
quantity accumulates inside the DC compared to natural
allergen. Recombinant and natural Der p 1 both co-localised with
LAMP-2, a lysosomal marker, suggesting a common fate for
these preparations inside the DC. There is a possibility that the
apparent differences in staining with rDerp1 and nDerp1 could
be due to differences in labelling efficiencies with the
fluorochrome preparations and/or other differences in the Derp1
preparations (unrelated to glycosylation levels). However, the
confocal results are consistent with the flow cytometry studies
that indicate higher uptake of rDerp1 when using the same
fluorochromes for both rDerp1 and nDerp1 preparations, and
also with ELISA studies of binding to MR using unlabelled Derp1
preparations.
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The uptake of the non-allergenic protein Staphopain B, a
cysteine protease from Staphylococcus aureus, was significantly
lower than that of nDer p 1 (also a cysteine protease), as shown
by confocal imaging and FACS. This was expected as this
cysteine protease is not mannosylated (see chapter 2).
This chapter also showed that the different glycoforms of Der p1
bind less to the lectin-like carbohydrate recognition domains 4-7
of MR compared to the native one. This is expected as these
glycoforms proved to have less mannan than the natural
preparation. The fact that they lost their sugar content did not
affect the whole protein structure as they still bind to anti-Der p
1 5H8. This indicates that they have the same conformation as
natural allergens.
Der p 1 is an allergen that induces Th2 immune response which
provokes high IL-4, IL-5 and IL-13 cytokine secretions by T cells
and increase secretion of TSLP by epithelial cells. This finding
seems to change when challenging human epithelial cells with a
deglycosylated preparation of Der p 1. The TSLP secretion is
reduced when culturing the epithelial cells with different
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deglycosylated forms of Der p 1 compared to the natural
preparations.
Upon stimulating DCs with the different concentrations of TSLP
containing media (produced by Der p 1 glycoforms stimulation of
epithelial cells) and co-culturing them with T cells in vitro, it
seems that low concentrations of TSLP induced the production of
lower IL-4,5 and 13 by T cells on average in some donors and a
high concentrations of TSLP stimulated T cells to produce higher
IL-4, 5 and 13. In some experiments low TSLP concentrations
produced through deglycosylating Der p 1 induced higher IFN-ɶ
and lower IL-5 and IL-13 indicating a shift towards Th1 immune
response when using deglycosylated Der p 1 allergen in some
donors. Using an antibody against TSLP in the same media
showed that the cytokine secretions by T cells decreased on
average which suggests that TSLP cytokine is responsible for
increasing IL-5 and IL-13 cytokine secretion.
In conclusion, glycosylation is clearly a key feature of many
allergens (as described in chapter 2), and mannan seems to be
the dominant sugar moiety associated with allergens. It is
therefore not surprising that MR plays such a significant role in
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the recognition and internalisation of many diverse allergens
(Royer et al, 2010). This chapter investigated the nature of
glycoallergen recognition by DCs through studying the uptake of
labelled hyper and hypo-glycosylated preparations of Der p 1.
Data generated provided an insight into the effect of
mannosylation on Der p 1 recognition and uptake by DCs.
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CHAPTER FIVE: General discussion
The role of allergen glycosylation in allergy has not been fully
elucidated yet. Many allergens are naturally glycosylated and
are known to contain carbohydrate determinants of xylose
and fucose, and this raises the possibility that the specific
glycosyl groups may contribute to allergens immunogenicity
and allergenicity. The main aim of this project was to clarify
the role of protein glycosylation in allergens recognition by
the innate immune system. This was assessed through
investigating the pattern of glycosylation in major allergens
like Der p 1, Fel d 1, Ara h 1, Ber e 1, Der p 2, Bla g 2, Can f
1, Bromelain and Papain by using specified lectins like GNA,
which helped defining N-glycosylation. We also used SNA,
MAA, PNA and DSA that recognised specific O-glycosylation.
These experiments showed that all major allergens are indeed
glycosylated and this represented a major first step towards
demonstrating a link between glycosylation and allergen
recognition by the innate immune system. Most of the
previous research carried out on allergen glycosylation
reported the presence of xylose and fucose (Altmann, 2007,
Chunsheng et al., 2008). We, however, found that the main
dominant sugars on allergens are 1,2 1,3 and 1,6 mannose,
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as detected by GNA lectin, and this was present in high
quantities in allergens like Ara h 1, Bla g 2 and Papain
compared to non-allergens. We have also shown that Der p 1
and Der p 2 possess 1,3 fucose in their natural forms, thus
concluding that Der p1 and Der p 2 have part of the CCDs
which are epitope structures for IgE. This was not reported
before and therefore aided our attempts to have a better
understanding of allergen N and O-glycosylation patterns as a
whole. We were also able to describe differences in
glycosylation patterns between allergens and non-allergens,
which were mainly due to variation in mannosylation and
fucosylation.
Comparative carbohydrate analysis between allergens and
non-allergens from the cysteine protease family, which
included Der p 1, Papain and Bromelain as allergens and
Staphopain B, Calpain and Cysteine Protease B (CPB) as non-
allergens, indicated that the non-allergens Staphopain B and
Calpain do not react with GNA, and thus are not
mannosylated like allergens. Cysteine protease B showed a
very weak reaction with GNA, again indicating that it has only
a minimal amount of mannose moities. Staphopain B also did
not react with any of the other lectins, indicating that it does
not have any O-glycosylation.
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We were able to predict N-glycosylation structures on major
allergens when combining the data we obtained from lectin
reactivity with the data already present in the literature. Der p
1 for example reacted with GNA and 1,3 fucose and the
literature reported that xylose is present in Der p 1. Thus, its
N-glycosylation pattern was predicted with the help of
symbolic representation suggested by the Consortium of
Functional Glycomics. Similar speculations were done for
several major allergens like Ara h 1, Bla g 2, Can f 1 and Fel d
1 (Fig 2-10). A pattern for the difference in quantity of
mannosylation emerged between allergens and non-allergens,
which can be concluded by saying that non-allergens possess
a very low quantity of mannose and fucose 1, 3.
O-glycosylation in allergens was also studied thoroughly
through SNA, MAA, PNA and DSA lectin reactivities, giving a
better understanding of the whole glycan structure in
allergens.
The second step was to study if any changes in the sugar
content of allergens would affect their recognition by the
immune system. This was facilitated through optimising
different methods to produce glycoforms of the same allergen
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and assess their recognition by cells of the innate immune
system.
In an attempt to express a recombinant hyperglycosylated
form of Der p 1 allergen in Pichia pastoris, which is known to
produce hypermannosylated proteins, Der p 1 cDNA was
successfully amplified from a phage library, sequenced,
inserted into a vector, transformed to TOP 10 cells for
amplification and concentration. The vector was then purified,
concentrated, transformed to Pichia yeast X33 competent
cells and expressed. In order to produce deglycosylated
forms of Der p 1 allergen, mutations to possible glycosylation
sites (N16, N82, N132, N195) in the proDer p 1 amplicon
were done and sequenced then expressed in Pichia. Again
these mutants were successfully inserted into a vector,
transformed to TOP 10 cells for amplification. The vector was
then purified, concentrated, transformed to Pichia competent
cells and expressed. We were able to show that Der p1 and
its deglycosylated mutants were expressed in Pichia as they
reacted to 5H8 anti Der p 1 antibody. However, the
expression of these amplicons in yeast seemed to be affected
by culture proteases resulting in degradation, thus other
methods with more consistent results were optimised to
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produce these glycoforms, which are discussed in chapter
four.
By optimising enzymatic and chemical deglycosylation
methods, we were able to produce different glycoforms of Der
p 1 which proved to possess less mannan than the natural
allergen when reacting with GNA. A commercially available
recombinant preparation was used as a hyperglycosylated
allergen for Der p 1 and was shown to be highly
mannosylated compared to the natural form. All these
glycoforms reacted with anti-Der p 1 5H8 antibody, which
confirms that the allergen conformation and epitope structure
remained intact. These glycoforms were useful tools in
addressing the glycoallergen recognition pattern by looking
directly at the uptake of fluorochrome labelled hyper- and
hypo-glycosylated preparations of the same allergen by DCs
via confocal microscopy, ELISA and FACS studies.
Comparative analysis of the recombinant hypermannosylated
preparation of Der p 1 and its natural counterpart, which
possess less mannan, showed that the recombinant form was
taken up more readily by DCs at 37°C and at 4°C, as shown by
FACS and confocal imaging (Figs 4-1, 4-2). The recombinant
preparation was also able to inhibit the uptake of natural Der
p 1 by DCs in a concentration dependent manner (Fig 4-4).
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Furthermore, the uptake of the deglycosylated recombinant
preparation of Der p 1 (N52Q) was less than that of the
recombinant glycosylated preparation (Fig 4-3). This strongly
suggests a role for glycosylation in uptake by immature DCs.
When using the periodate deglycosylated Der p 1 and
enzymatically deglycosylated Der p 1, they were not
internalised in the same manner by DCs as their glycosylated
counterpart and both exhibited minimal uptake by DCs as
shown by FACS and confocal analysis (Figs 4-16, 4-21). The
deglycosylated preparations of the allergen had minimal
mannan as shown by western blotting against anti-mannose
GNA (Fig 4-19), suggesting a key role for mannan in allergen
uptake by DCs. A completely demannosylated Der p 1
allergen failed to be internalised by DCs as shown by confocal
and FACS studies in chapter four (Figs 4-21, 4-23). The
uptake of the non-allergen Staphopain B by DCs was minimal
compared to allergens, even though this protein is a cysteine
protease just like Der p 1. This may be due to the fact that
this protein is not mannosylated as shown in chapter 2.
Results also indicate that galactose has no significant effect
on the uptake of Der p 1 by DCs (Fig 4-26).
The confocal images showed that the internalization of Der p
1 is initiated by MR on immature DCs. Recombinant and
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natural Der p 1 both co-localised with MR, DC-SIGN and
LAMP-2, albeit with different kinetics, which indicates a
common fate for these preparations inside the DC. We also
showed by ELISA experiments that these glycoforms bind to
the MR subfragment CTLD 4-7, the C-type lectin carbohydrate
recognition domain, and this is consistent with their
carbohydrate content. Results show a significant decrease in
binding to MR (>55%) when the Der p 1 allergen is
deglycosylated with periodate for 60 mins. The same is
noticed when treating hypermannosylated rDer p 1 with
periodate for 60 mins, as the decrease in binding after
deglycosylation reached 42.5%. It is clear that the binding of
the recombinant preparation of Der p 1 to MR is much
stronger than that of natural Der p 1 which is expected as
rDer p 1 has more mannan than natural Der p 1 (shown in
chapter 2).
Dendritic cells are specialised antigen presenting cells that
direct the immune systems towards development of Th1 or
Th2 immune responses. DCs express C-type lectin receptors
that serve as antigen receptors allowing internalization and
antigen presentation and also serve as signalling molecules.
Several groups have demonstrated that glycan modification of
antigens can change its presentation (Adams et al., 2008,
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Aarnoudse et al., 2008, Mitsuhiro et al., 2001). Glycan
modified ovalbumin having lewis oligosaccharides enhanced
both CD4+ and CD8+ T cell responses (Singh et al., 2009,
Wang et al., 2007). Others demonstrated that high mannose
modified melanoma antigen enhanced antigen presentation to
CD4+ T cells (Aarnoudse et al., 2008). Potentially lower or
slower uptake upon deglycosylation of allergens could lead to
change in the outcome of the innate and adaptive immune
responses. This was presented in literature when
Carbohydrates on Cry j 1 were destroyed by periodate-
oxidation which resulted in significant decrease in T cells
proliferation and a decrease in IL-4,5 production ( Mitsuhiro et
al., 2001).
This work addressed the nature of glycoallergen recognition
through looking at the recognition and uptake of hyper- and
hypo-glycosylated preparations of Der p 1. As allergens
influence both innate and adaptive immune responses and
favour Th2 immunity, it would be interesting to know if
deglycosylated allergens stimulate the immune system
differently. There is a substantial body of evidence showing
that the encounter of allergens with epithelial cells induce
TSLP secretion, which activates DCs allowing them to prime
naive T cells for the production of pro-inflammatory cytokines
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(Roggen et al., 2006). TSLP has been shown to induce IL-4, 5
and 13 driven allergic inflammation and upregulates MHC I
and II co-stimulatory molecules CD40, CD80, CD83 and CD86
(Wang and Xing, 2008, Wang and Liu, 2009, Friend SL, 1994,
Ray et al., 1996, Tanaka et al., 2009, Miyata et al., 2009,
Soumelis et al., 2002).
In this work, some experiments were done to show the effect
of Der p 1 and Der p 1 glycoforms on TSLP secretion in vitro.
We showed that there is a significant increase in the secretion
of TSLP by epithelial cells when encountering Der p 1
compared to the control, and that TSLP secretion decreases
significantly when epithelial cells are challenged with
deglycosylated preparations of the same allergen. This
observation should now pave the way for looking at the
differential expression of Th1/Th2 cytokines following
exposure of epithelial cells to different allergen glycoforms
and co-culturing TSLP-conditioned DCs with T cells
More work is needed to have a better understanding of the
effect of carbohydrates on adaptive immunity and if
differences in glycosylation patterns could explain why certain
proteins act as allergens. This could be facilitated by
producing differen
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through chemical deglycosylation or recombinant expression
and examining their recognition by APCs and their
downstream effects on T cells.
There is considerable interest in defining why allergens are
allergens. This work has clearly progressed the notion that
allergenicity is possibly linked to the glycosylation pattern of
allergens. It is therefore reasonable to conclude that mannan
seems to be the dominant sugar moiety associated with
allergens, and this is consistent with MR being the main
receptor involved in allergen recognition and uptake by DCs.
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